3 - Defining and measuring Bipolar II Disorder  pp. 46-60


By Gordon Parker

Image View Previous Chapter Next Chapter



Introduction

In the last decade many commentators have stated that Bipolar II Disorder (BP II) is under-diagnosed. Over the same period, many others have stated that it is over-diagnosed. Such contradictory views hint at problems with definition and diagnosis – and reflect the controversy as to whether it is a true condition or more a personality style. As it is also commonly viewed as lying along a spectrum of mood disorders bounded by Bipolar I Disorder (BP I) and unipolar depressive conditions (see Chapter 2), we can assume that ‘boundary’ problems (in differentiating one condition clearly from the other) also contribute to difficulties in diagnostic delineation.

In Chapter 2, Phelps well argued the salience of a ‘spectrum’ model. In this chapter, an opposing categorical model is offered for consideration. This does reflect a personal view that bipolar disorder is a categorical condition or an ‘entity’, and further, that if distinctive sub-set diagnoses (of BP I and BP II) exist, distinction between them must be meaningful (in inferring differing clinical pictures and causes, and/or salient differential treatments). Medicine advanced by distinguishing differing clinicopathological expressions of the ‘pox’ (i.e. smallpox and chickenpox), differing causes of ‘dropsy’ (e.g. renal and cardiac) and in distinguishing Type I and Type II diabetes. All three examples (i.e. the ‘pox’, ‘dropsy’ and diabetes) could have been dimensionally modelled, but explanatory power would have been less, while aetiological and treatment implications would have been obscured.

Reference Title: REFERENCES

Reference Type: reference-list

Dr Geoff Gallop (2006). Press release. Statement from the Premier of Western Australia. Content authorised by the Government Media Office, Department of the Premier and Cabinet, 16 January.

Reference Title: REFERENCES

Reference Type: reference-list

American Psychiatric Association (1980). Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: APA.
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn: Text Revision, DSM–IV–TR. Washington, DC: APA.
Angst, J. (1966). Zur Ätiologie und Nosologie endogener depressiver Psychosen: Eine genetische, soziologische und klinische Studie. Berlin: Springer.
Baillarger, J. (1854a). De la folie à double forme. Annales Médico-psychologiques, 6, 369–91.
Baillarger, J. (1854b). (Response in discussion – no title). Bulletin de l'Académie de Médecine, 19, 401–15.
Ban, T. (1990). Clinical pharmacology and Leonhard's classification of endogenous psychoses. Psychopathology, 23, 331–8.
Carroll, B. (1994). Brain mechanisms in manic depression. Clinical Chemistry, 40, 303–8.
Chiarugi, V. (1794). Della Pazzia in Genere e in Specie. Trattato Medico-analitico, Vol. 3. Florence: Carlieri.
Falret, J. P. (1854). Mémoire sur la folie circulaire. Bulletin de l'Académie de Médecine, 19, 382–400.
Feighner, J., Robins, E., Guze, S., Woodruff, R., Winokur, G. and Munoz, R. (1972). Diagnostic criteria for use in psychiatric research. Archive of General Psychiatry, 26, 57–63.
Flemming, C. (1844). Über Classification der Seelenstörungen. Allgemeine Zeitschrift für Psychiatrie, 1, 97–130.
Healy, D. (2006). The latest mania: Selling bipolar disorder. PLOS Medicine, www.plosmedicine.org, 3(4), e185.
Irschitzky (1838). Über psychische Krankheiten im Districts-Physikate Voitsberg. Medicinische Jahrbücher des k. k. Österreichischen Staates, 17, 233–47.
Jackson, S. (1986). Melancholia and Depression From Hippocratic Times to Modern Times. New Haven, NJ: Yale.
Kahlbaum, K. (1882). Über cyklisches Irresein. Der Irrenfreund, 24, 145–57.
Kirchhoff, T. (1924). Deutsche Irrenärzte, Vol. 2. Berlin: Springer.
Kirn, L. (1878). Die Periodischen Psychosen. Stuttgart: Enke.
Kleist, K. (1911). Die klinische Stellung der Motilitätspsychosen. Zeitschrift für die gesamte Neurologie und Psychiatrie, 3, 914–17.
Kleist, K. (1926). Über zykloide Degenerationspsychosen, besonders Verwirrtheits- und Motilitätspsychosen. Archiv für Psychiatrie und Nervenkrankheiten, 78, 416–21.
Kleist, K. (1928). Über zykloide, paranoide und epileptoide Psychosen und über die Frage der Degenerationspsychosen. Schweizer Archiv für Neurologie und Psychiatrie, 23, 3–37.
Kraepelin, E. (1899). Psychiatrie: ein Lehrbuch, 6th edn, Vol. 2. Leipzig: Barth.
Kraepelin, E. (1904). Psychiatrie: ein Lehrbuch, 7th edn, Vol. 2. Leipzig: Barth.
Leonhard, K. (1957). Aufteilung der Endogenen Psychosen. Berlin: Akademie-Verlag.
Mendel, E. (1881). Die Manie. Vienna: Urban.
Neele, E. (1949). Die phasischen Psychosen nach ihrem Erscheinungs- und Erbbild. Leipzig: Barth.
Penrose, T. (1775). Flights of Fancy. London: Walter.
Perris, C. (1966). A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatrica Scandinavica, 42 (Suppl. 194), S1–S189.
Shorter, E. (2005). Historical Dictionary of Psychiatry. New York: Oxford University Press.
Spitzer, R., Endicott, J., Robins, E., Kuriansky, J. and Gurland, B. (1975). Preliminary report of the reliability of Research Diagnostic Criteria applied to psychiatric case records. In Predictability in Psychopharmacology: Preclinical and Clinical Correlations, ed. A. Sudilovsky, S. Gershon & B. Beer, pp. 1–47. New York: Raven.
Spitzer, R., Endicott, J. and Robins, E. (1978). Research Diagnostic Criteria. Archives of General Psychiatry, 35, 773–82.
Taylor, M. and Abrams, R. (1980). Reassessing the bipolar-unipolar dichotomy. Journal of Affective Disorders, 2, 195–217.
Taylor, M. and Fink, M. (2006). Melancholia: The Diagnosis, Pathophysiology, and Treatment of Depressive Illness. New York: Cambridge University Press.
Wernicke, C. (1900). Grundriss der Psychiatrie, part 3. Leipzig: Thieme.
Weygandt, W. (1899). Über die Mischzustände des manisch-depressiven Irreseins. Munich: Lehmann.
Winokur, G. (1991). Mania and Depression: A Classification of Syndrome and Disease. Baltimore, MD: Johns Hopkins University Press.
Winokur, G. and Clayton, P. (1967). Family history studies I. Two types of affective disorders separated according to genetic and clinical factors. In Recent Advances in Biological Psychiatry, ed. J. Wortis, pp. 25–30. New York: Plenum.

Reference Title: FURTHER READING

Reference Type: reference-list

El-Mallakh, R. S. and Ghaemi, S. N. (2006). Bipolar Depression. Washington, DC: American Psychiatric Publishing.
Ghaemi, S. N., Ko, J. Y. and Goodwin, F. K. (2002). ‘Cade's disease’ and beyond: Misdiagnosis, antidepressant use, and a proposed definition for Bipolar Spectrum Disorder. Canadian Journal of Psychiatry, 47, 125–34.
International Society for Bipolar Disorders (2006). Diagnostic Guidelines Task Force Report. Bipolar Disorders Special Issue, in review.
Phelps, J. (2006). Mood Swings without Mania: Bipolar II. http://www.PsychEducation.org, accessed 12/1/06.
Phelps, J. (2006). Why Am I Still Depressed? Recognising and Managing the Ups and Downs of Bipolar II and Soft Bipolar Disorders. New York: McGraw-Hill.

Reference Title: REFERENCES

Reference Type: reference-list

Akiskal, H. S. and Benazzi, F. (2006). Recurrent Major Depressive Disorder and Bipolar II: evidence that they lie on a dimensional spectrum. Journal of Affective Disorders, 92, 45–54.
Akiskal, H. S. and Mallya, G. (1987). Criteria for the ‘soft’ bipolar spectrum: treatment implications. Psychopharmacological Bulletin, 23, 68–73.
Akiskal, H. S. and Pinto, O. (1999). The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatric Clinics of North America, 22, 517–34.
Amsterdam, J. D. and Brunswick, D. J. (2003). Antidepressant monotherapy for Bipolar Type II major depression. Bipolar Disorders, 5, 388–95.
Angst, J. and Cassano, G. (2005). The mood spectrum: improving the diagnosis of bipolar disorder. Bipolar Disorders, 7 (Suppl. 4), S4–12.
Angst, J., Gamma, A., Benazzi, F. et al. (2003). Toward a re-definition of sub-threshold bipolarity: epidemiology and proposed criteria for Bipolar-II, minor bipolar disorders and hypomania. Journal of Affective Disorders, 73, 133–46.
Benazzi, F. (2003). Bipolar II Disorder and major depressive disorder: continuity or discontinuity? World Journal of Biological Psychiatry, 4, 166–71.
Berk, M. and Dodd, S. (2005). Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression? Medical Hypotheses, 65, 39–43.
Cassano, G. B., Rucci, P., Frank, E. et al. (2004). The mood spectrum in unipolar and bipolar disorder: arguments for a unitary approach. American Journal of Psychiatry, 161, 1264–9.
Dunner, D. L. (2003). Clinical consequences of under-recognized bipolar spectrum disorder. Bipolar Disorders, 5, 456–63.
El-Mallakh, R. S. and Ghaemi, S. N. (2006). Bipolar Depression. Washington, DC: American Psychiatric Publishing.
El-Mallakh, R. S. and Karippot, A. (2005). Antidepressant-associated chronic irritable dysphoria (acid) in bipolar disorder: A case series. Journal of Affective Disorders, 84, 267–72.
Frye, M. A., McElroy, S. L., Helleman, G. (2006). Clinical correlates associated with treatment-emergent mania. Poster presentation, American Psychiatric Association, Toronto.
Ghaemi, S. N., Daversa, C., Bauer, M. et al. (2006). Summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report. Bipolar Disorders, in review.
Ghaemi, S. N., Ko, J. Y. and Goodwin, F. K. (2002). ‘Cade's disease’ and beyond: Misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Canadian Journal of Psychiatry, 47, 125–34.
Ghaemi, S. N., Miller, C. J., Berv, D. A. et al. (2005). Sensitivity and specificity of a new bipolar spectrum diagnostic scale. Journal of Affective Disorders, 84, 273–7.
Ghaemi, S. N., Saggese, B. A. and Goodwin, F. K. (2006). Diagnosis of Bipolar Depression. In Bipolar Depression, ed. R. S. El-Mallakh and N. S. Ghaemi. Washington, DC: American Psychiatric Publishing.
Gijsman, H. J., Geddes, J. R., Rendell, J. M., Nolen, W. A. and Goodwin, G. M. (2004). Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. American Journal of Psychiatry, 161, 1537–47.
Goldberg, J. F. and Truman, C. J. (2003). Antidepressant-induced mania: an overview of current controversies. Bipolar Disorders, 5, 407–20.
Kessler, R. (2005). Prevalence and effects of mood disorders on role performance in the United States. Presented at the annual meeting of the International Society for Bipolar Disorders, Pittsburgh, PA.
Katzow, J. J., Hsu, D. J. and Ghaemi, S. N. (2003). The bipolar spectrum: a clinical perspective. Bipolar Disorders, 5, 436–42.
Klerman, G. L. (1981). The spectrum of mania. Comprehensive Psychiatry, 22, 11–20.
Leverich, G. S., Altshuler, L. L., Frye, M. A. et al. (2006). Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. American Journal of Psychiatry, 163, 232–9.
Mackinnon, D. F. and Pies, R. (2006). Affective instability as rapid cycling: theoretical and clinical implications for borderline personality and bipolar spectrum disorders. Bipolar Disorders, 8, 1–14.
Mitchell, P., Goodwin, G., Johnson, G. and Hirschfeld, R. (2006). Diagnostic guidelines for Bipolar I depression: A probabilistic approach. Bipolar Disorders, in review.
Mondimore, F. M. (2005). Unipolar depression/bipolar depression: connections and controversies. International Review of Psychiatry, 17, 39–47.
Moller, H. J. and Curtis, V. A. (2004). The bipolar spectrum: Diagnostic and pharmacologic considerations. Expert Review of Neurotherapeutics, 4 (Suppl. 2), S3–8.
Parker, G., Tully, L., Olley, A. and Hadzi-Pavlovic, D. (2006). SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of Affective Disorders, 92, 205–14.
Phelps, J. (2005a). Using the MDQ in Primary Care: Predictive value of the test results. http://www.psycheducation.org/PCP/mdqSensSpec.htm, accessed 12/7/2006.
Phelps, J. R. (2005b). Agitated dysphoria after late-onset loss of response to antidepressants: a case report. Journal of Affective Disorders, 86, 277–80.
Phelps, J. (2006). Depression is not a moral weakness. http://www.psycheducation.org/mechanism/MechanismIntro.htm, accessed 12/7/06.
Phelps, J. R., Angst, J., Katzow, J. and Sadler, J. (2006). Validity and utility of the Bipolar Spectrum. Bipolar Disorders, in review.
Phelps, J. R. and Ghaemi, S. N. (2006). Improving the diagnosis of bipolar disorder: predictive value of screening tests. Journal of Affective Disorders, 92, 141–8.
Quitkin, F. M., Kane, J., Rifkin, A., Ramos-Lorenzi, J. R. and Nayak, D. V. (1981). Prophylactic lithium carbonate with and without imipramine for Bipolar I patients. A double-blind study. Archives of General Psychiatry, 38, 902–7.
Skeppar, P. and Adolfsson, R. (2006). Bipolar II and the bipolar spectrum. Nordic Journal of Psychiatry, 60, 7–26.
Wehr, T. and Goodwin, F. K. (1979). Tricyclics modulate frequency of mood cycles. Chronobiologia, 6, 377–85.

Reference Title: REFERENCES

Reference Type: reference-list

Angst, J., Adolfsson, R., Benazzi, F. et al. (2005). The HCL-32: Towards a self-assessment tool for hypomanic symptoms in patients. Journal of Affective Disorders, 88, 217–33.
Angst, J., Gamma, A., Benazzi, F. et al. (2003). Toward a re-definition of sub-threshold bipolarity: Epidemiology and proposed criteria for Bipolar-II, minor bipolar disorders and hypomania. Journal of Affective Disorders, 73, 133–46.
Hirschfeld, R. M. A., Williams, J. B. W., Spitzer, R. L. et al. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire. American Journal of Psychiatry, 157, 1873–5.
Parker, G. (2000). Classifying depression: should paradigms lost be regained? American Journal of Psychiatry, 157, 1195–203.
Parker, G., Hadzi-Pavlovic, D. and Tully, L. (2006). Distinguishing bipolar and unipolar disorders: an isomer model. Journal of Affective Disorders, 96, 67–73.
Tully, L. and Parker, G. (2007). How low do we go? Is duration of a ‘high’ integral to the definition of bipolar disorder? Acta Neuropsychiatrica, 19, 38–44.

Reference Title: REFERENCES

Reference Type: reference-list

Akiskal, H. S. and Pinto, O. (1999). The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatric Clinics of North America, 22, 517–34.
Akiskal, H. S., Bourgeois, M. L., Angst, J. et al. (2000). Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. Journal of Affective Disorders, 59 (Suppl. 1), S5–30.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
Angst, J. (1998). The emerging epidemiology of hypomania and Bipolar II Disorder. Journal of Affective Disorders, 50, 143–51.
Angst, J. (2006). Do many patients with depression suffer from bipolar disorder? Canadian Journal of Psychiatry, 51, 3–5.
Angst, J., Gamma, A., Benazzi, F. et al. (2003a). Toward a re-definition of sub-threshold bipolarity: Epidemiology and proposed criteria for Bipolar II, minor bipolar disorders and hypomania. Journal of Affective Disorders, 73, 133–46.
Angst, J., Gamma, A., Benazzi, F. et al. (2003b). Diagnostic issues in bipolar disorder. European Neuropsychopharmacology, 13 (Suppl. 2), S43–50.
Baethge, C., Salvatore, P. and Baldessarini, R. J. (2003). Introduction to Cyclothymia, a circular mood disorder, by Ewald Hecker. History of Psychiatry, 14, 377–99.
Baldessarini, R. J. (2000). A plea for integrity of the bipolar disorder concept. Bipolar Disorders, 2, 3–7.
Baldessarini, R. J., Tondo, L., Floris, G. and Hennen, J. (1998). Effects of rapid cycling on response to lithium maintenance treatment in 360 Bipolar I and II Disorder patients. Journal of Affective Disorders, 155, 1434–6.
Bauer, M. and Pfenning, A. (2005). Epidemiology of bipolar disorders. Epilepsia, 46 (Suppl. 4), S8–13.
Benazzi, F. (2000). Borderline Personality Disorder and Bipolar II Disorder in private practice depressed outpatients. Comprehensive Psychiatry, 41, 106–10.
Benazzi, F. (2001a). Course and outcome of Bipolar II Disorder: A retrospective study. Psychiatry and Clinical Neurosciences, 55, 67–70.
Benazzi, F. (2001b). Is four days the minimum duration of hypomania in Bipolar II Disorder? European Archives of Psychiatry and Clinical Neuroscience, 251, 32–4.
Benazzi, F. (2004). Bipolar II Disorder family history using the family history screen: findings and clinical implications. Comprehensive Psychiatry, 45, 77–82.
Coryell, W., Endicott, J., Maser, J. D. et al. (1995). Long-term stability of polarity distinctions in the affective disorders. American Journal of Psychiatry, 152, 385–90.
Coryell, W., Endicott, J., Reich, T., Andreasen, N. and Keller, M. A. (1984). A family study of Bipolar II Disorder. British Journal of Psychiatry, 145, 49–54.
Coryell, W., Solomon, D., Turvey, C. et al. (2003). The long-term course of rapid-cycling bipolar disorder. Archives of General Psychiatry, 60, 914–20.
Das Gupta, R. and Guest, J. F. (2002). Annual cost of bipolar disorder to UK society. British Journal of Psychiatry, 180, 227–33.
Dunner, D. L., Gershon, E. S. and Goodwin, F. K. (1976). Heritable factors in the severity of affective illness. Biological Psychiatry, 11, 31–42.
Ghaemi, S. N., Hsu, D. J., Soldani, F. and Goodwin, F. K. (2003). Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders, 5, 421–33.
Ghaemi, S. N., Ko, J. Y. and Goodwin, F. K. (2002). ‘Cade's disease’ and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Canadian Journal of Psychiatry, 47, 125–34.
Goodwin, G. (2002). Hypomania: what's in a name? British Journal of Psychiatry, 181, 94–5.
Goodwin, F. K. and Jamison, K. R. (1990). Manic Depressive Illness. New York: Oxford University Press.
Gunderson, J. G., Weinberg, I., Daversa, M. T. et al. (2005). Descriptive and longitudinal observations on the relationship of Borderline Personality Disorder and bipolar disorder. American Journal of Psychiatry, 163, 1173–8.
Hadjipavlou, G. H. and Yatham, L. (2004). Bipolar II Disorder: an overview of recent developments. Canadian Journal of Psychiatry, 49, 802–12.
Hantouche, E. G., Akiskal, H. S., Lancrenon, S. et al. (1998). Systematic clinical methodology for validating Bipolar II Disorder: Data in mid-stream from a French national multi-site study (EPIDEP). Journal of Affective Disorders, 50, 163–73.
Hirschfeld, R. M. A. and Vornik, A. L. (2005). Bipolar disorder – costs and comorbidity. American Journal of Managed Care, 11 (Suppl. 3), S85–90.
Hirschfeld, R. M., Williams, J. B., Spitzer, R. L. et al. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. American Journal of Psychiatry, 157, 1873–5.
Isometsa, E., Suominen, K., Mantere, O. et al. (2003). The Mood Disorder Questionnaire improves recognition of bipolar disorder in psychiatric care. BMC Psychiatry, 3 (1), 8.
Joffe, R. T., MacQueen, G. M., Marriott, M. and Young, L. T. (2004). A prospective, longitudinal study of percentage of time spent ill in patients with Bipolar I or Bipolar II disorders. Bipolar Disorders, 6, 62–6.
Joyce, P. R., Luty, S. E., McKenzie, J. M. et al. (2004). Bipolar II Disorder: personality and outcome in two clinical samples. Australian and New Zealand Journal of Psychiatry, 38, 433–8.
Judd, L. L. and Akiskal, H. S. (2003). The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account sub-threshold cases. Journal of Affective Disorders, 73, 123–31.
Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of Bipolar II Disorder. Archives of General Psychiatry, 60, 261–9.
Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2005). Psychosocial disability in the course of Bipolar I and II Disorders. A prospective, comparative, longitudinal study. Archives of General Psychiatry, 62, 1322–30.
Katzow, J. J., Hsu, D. J. and Nassir, G. S. (2003). The bipolar spectrum: a clinical perspective. Bipolar Disorders, 5, 436–42.
Kessler, R. C., Akiskal, H. S., Ames, M. et al. (2006). Prevalence and effect of mood disorders on work performance in a nationally representative sample of U.S. workers. American Journal of Psychiatry, 163, 1561–8.
Kessler, R. C., Berglund, P., Demler, O. et al. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry, 62, 593–602.
Kleinman, L. S., Lowin, A., Flood, E. et al. (2003). Costs of bipolar disorder. Pharmacoeconomics, 21, 601–22.
Koukopoulos, A. (2003). Ewald Hecker's description of cyclothymic mood disorder: its relevance to the modern concept of Bipolar II. Journal of Affective Disorders, 73, 199–205.
Krishnan, K. R. R. (2005). Psychiatric and medical comorbidities of bipolar disorder. Psychosomatic Medicine, 67, 1–8.
Kupfer, D. J. (2005). The increasing medical burden of bipolar disorder. Journal of the American Medical Association, 293, 528–30.
Li, J., McCombs, J. S. and Stimmel, G. L. (2002). Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. Journal of Affective Disorders, 71, 131–9.
McElroy, S. L., Altshuler, L. L., Suppes, T. et al. (2001). Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. American Journal of Psychiatry, 158, 420–6.
MacQueen, G. M. and Young, L. T. (2001). Bipolar II Disorder: symptoms, course, and response to treatment. Psychiatric Services, 52, 358–61.
Magill, C. A. (2004). The boundary between Borderline Personality Disorder and bipolar disorder: Current concepts and challenges. Canadian Journal of Psychiatry, 49, 551–6.
Pini, S., de Queiroz, V., Pagnin, D. et al. (2005). Prevalence and burden of bipolar disorders in European countries. European Psychopharmacology, 15, 425–34.
Rihmer, Z. and Pestality, P. (1999). Bipolar II Disorder and suicidal behavior. Psychiatric Clinics of North America, 22, 667–73.
Shi, L., Thiebaud, P. and McCombs, J. S. (2004). The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program. Journal of Affective Disorders, 82, 373–83.
Simon, N. M., Otto, M. W., Wisniewski, S. R. et al. for the STEP-BD Investigators (2004). Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). American Journal of Psychiatry, 161, 2222–9.
Simpson, S. G., Folstein, S. E., Meyers, D. A. et al. (1993). Bipolar II: the most common bipolar phenotype? American Journal of Psychiatry, 150, 901–3.
Simpson, S. G., McMahon, F. J., McInnis, M. G. et al. (2002). Diagnostic reliability of Bipolar II Disorder. Archives of General Psychiatry, 59, 736–40.
Stone, M. H. (2006). The relationship of Borderline Personality Disorder and bipolar disorder. American Journal of Psychiatry, 163, 1126–8.
Suppes, T., Mintz, J., McElroy, S. L. et al. (2005). Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network. Archives of General Psychiatry, 62, 1089–96.
Szádóczky, E., Papp, Z., Vitrai, J., Rihmer, Z. and Füredi, J. (1998). The prevalence of major depressive and bipolar disorder in Hungary. Results from a national epidemiologic survey. Journal of Affective Disorders, 50, 153–62.
Torrent, C., Martinez-Aran, A., Daban, C. et al. (2006). Cognitive impairment in Bipolar II Disorder. British Journal of Psychiatry, 189, 254–9.
Valtonen, H., Suominen, K., Mantere, O. et al. (2005). Suicidal ideation and attempts in Bipolar I and II disorders. Journal of Clinical Psychiatry, 66, 1456–62.
Yatham, L. (2004). Diagnosis and management of patients with Bipolar II Disorder. Journal of Clinical Psychiatry, 66 (Suppl. 1), S13–17.
Yatham, L. N., Kennedy, S. H., O'Donovan, C. et al. (2005). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disorders, 7 (Suppl. 3), S5–69.

Reference Title: REFERENCES

Reference Type: reference-list

Akiskal, H. S., Bourgeois, M. L., Angst, J. et al. (2000). Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. Journal of Affective Disorders, 59, S5–30.
Angst, J. (1998). The emerging epidemiology of hypomania and Bipolar II Disorder. Journal of Affective Disorders, 50, 143–51.
Angst, J., Gamma, A., Benazzi, F. et al. (2003). Toward a re-definition of sub-threshold bipolarity: epidemiology and proposed criteria for Bipolar II, minor bipolar disorders and hypomania. Journal of Affective Disorders, 73, 133–46.
Goodwin, F. K. and Jamison, K. R. (1990). Manic-Depressive Illness. New York: Oxford University Press.
Grant, B. F., Stinson, F. S., Hasin, D. S. et al. (2005). Prevalence, correlates, and comorbidity of Bipolar I Disorder and Axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry, 66, 1205–15.
Kessler, R. C., Berglund, P., Demier, O. et al. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 593–602.
Kessler, R. C., McGonagle, K. A., Zhao, S. et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry, 51, 8–19.
Oakley-Browne, M. A., Wells, J. E., Scott, K. M. and McGee, M. A. (2006). Lifetime prevalence and projected lifetime risk of DSM-IV disorders in Te Rau Hinengaro: The New Zealand Mental Health Survey. Australian and New Zealand Journal of Psychiatry, 40, 865–74.
Parker, G., Brotchie, H. and Fletcher, K. (2006). An increased proportional representation of bipolar disorder in younger depressed patients: analysis of two clinical databases. Journal of Affective Disorders, 95, 141–4.
Robins, L. N., Helzer, J. E., Weissman, M. M. et al. (1984). Lifetime prevalence of specific psychiatric disorders in three sites. Archives of General Psychiatry, 41, 949–58.

Reference Title: REFERENCES

Reference Type: reference-list

Baxter, L., Schwartz, J., Phelps, M. and Mazziotta, J. G. (1989). Reduction of prefrontal cortex glucose metabolism common to three types of depression. Archives of General Psychiatry, 46, 243–50.
Beckmann, H., St Laurent, J. and Goodwin, F. (1975). The effect of lithium on urinary MHPG in unipolar and bipolar depressed patients. Psychopharmacologia, 42, 277–82.
Berk, M., Bodemer, W., van Oudenhove, T. and Butkow, N. (1994). Dopamine increases platelet intracellular calcium in bipolar affective disorder and control subjects. International Clinical Psychopharmacology, 9, 291–3.
Berk, M., Bodemer, W. and van Oudenhove, T. (1995). The platelet intracellular calcium response to serotonin is augmented in bipolar manic and depressed patients. Human Psychopharmacology, 10, 189–93.
Berrettini, W., Nurnberger, J. R., Scheinin, M. et al. (1985). Cerebrospinal fluid and plasma monoamines and their metabolites in euthymic bipolar patients. Biological Psychiatry, 20, 257–69.
Bertolino, A., Frye, M., Callicott, J. et al. (2003). Neuronal pathology in the hippocampal area of patients with bipolar disorder: A study with proton magnetic resonance spectroscopic imaging. Biological Psychiatry, 53, 906–13.
Blumberg, H., Leung, H-C., Skudlarski, P. et al. (2003). A functional magnetic resonance imaging study of bipolar disorder. State- and trait-related dysfunction in ventral prefrontal cortices. Archives of General Psychiatry, 60, 601–9.
Brambilla, P., Nicoletti, J., Harenski, K. et al. (2002). Anatomical MRI study of subgenual prefrontal cortex in bipolar and unipolar subjects. Neuropsychopharmacology, 27, 792–9.
Brambilla, P., Nicoletti, M., Sassi, R. et al. (2004). Corpus callosum signal intensity in patients with bipolar and unipolar disorder. Journal of Neurology, Neurosurgery and Psychiatry, 75, 221–5.
Caligiuri, M., Brown, G., Meloy, M. et al. (2004). A functional magnetic resonance imaging study of cortical asymmetry in bipolar disorder. Bipolar Disorders, 6, 183–96.
Chang, K., Adelman, N., Dienes, K. et al. (2003). Decreased N-acetylaspartate in children and familial bipolar disorder. Biological Psychiatry, 53, 1059–65.
Davanzo, P., Thomas, M., Yeu, K. et al. (2001). Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology, 24, 359–69.
Dean, B., Opeskin, K., Pavey, G., Hill, C. and Keks, N. (1997). Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia. Journal of Neural Transmission, 104, 1371–81.
Deleon-Jones, F., Maas, J. and Dekermenjian, H. (1973). Urinary catecholamine metabolites during behavioral changes in patients with manic-depressive cycles. Science, 179, 300–2.
Drevets, W., Price, J., Simpson, J. Jr. et al. (1997). Subgenual prefrontal cortex abnormalities in mood disorders. Nature, 386, 824–7.
Dubovsky, S. and Franks, R. (1983). Intracellular calcium ions in affective disorders: A review and a hypothesis. Biological Psychiatry, 18, 781–97.
Dubovsky, S., Christiano, J., Daniell, L. et al. (1989). Increased platelet intracellular calcium concentration in patients with bipolar affective disorder. Archives of General Psychiatry, 46, 632–8.
Emamghoreishi, M., Schlichter, L., Li, P. P. et al. (1997). High intracellular calcium concentrations in transformed lymphoblasts from subjects with Bipolar I Disorder. American Journal of Psychiatry, 154, 976–82.
Friedman, S. D., Dager, S. R., Parow, A. et al. (2004). Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. Biological Psychiatry, 56, 340–8.
Gershon, E., Hamovit, J., Guroff, J. et al. (1982). A family study of schizoaffective, Bipolar I, Bipolar II, unipolar and normal control probands. Archives of General Psychiatry, 39, 1157–67.
Gottesman, I. I. and Gould, T. D. (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. American Journal of Psychiatry, 160, 636–45.
Grossman, F. and Potter, W. (1999). Catecholamines in depression: a cumulative study of urinary norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy volunteers at the NIMH. Psychiatry Research, 87, 21–7.
Gyulai, L., Alavi, A., Broich, K. et al. (1997). I-123 iofetamine single-photon computed emission tomography in rapid-cycling bipolar disorder: A clinical study. Biological Psychiatry, 41, 152–61.
Hamakawa, H. and Kato, T. (1998). Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 248, 53–8.
Hasler, G., Drevets, W. C., Gould, T. D., Gottesman, I. I. and Manji, H. K. (2006). Toward constructing an endophenotype strategy for bipolar disorders. Biological Psychiatry, 60, 93–105.
Heun, R. and Maier, W. (1993). The distinction of Bipolar II Disorder from Bipolar I and recurrent unipolar depression: results of a controlled family study. Acta Psychiatrica Scandinavica, 87, 279–84.
Hrdina, P., Faludi, G. L., Li, Q. et al. (1998). Growth associated protein (GAP-43), its mRNS, and protein kinase C (PKC) isoenzymes in brain regions of depressed suicides. Molecular Psychiatry, 3, 411–18.
Kato, T., Hamakawa, H., Shioiri, T. et al. (1996). Choline-containing compounds detected by proton magnetic resonance spectroscopy in the basal ganglia in bipolar disorder. Journal of Psychiatry and Neuroscience, 21, 248–53.
Kelly, T. (2007). Is donezepil useful for improving cognitive dysfunction in bipolar disorder? Journal of Affective Disorders, in press. DOI: 10.106/j.jad.2007.07.027.
Ketter, T., Kimbrell, T., George, M. et al. (2001). Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biological Psychiatry, 49, 97–109.
Lawrence, N., Williams, A., Surguladze, S. et al. (2004). Subcortical and ventral prefrontal cortical neural responses to facial expressions distinguish patients with bipolar disorder and major depression. Biological Psychiatry, 55, 578–87.
Malhi, G., Valenzuela, M., Wen, W. and Sachdev, P. (2002). Magnetic resonance spectroscopy and its application in psychiatry. Australian and New Zealand Journal of Psychiatry, 36, 31–43.
Malhi, G., Lagopoulos, J., Ward, P. et al. (2004a). Cognitive generation of affect in bipolar depression: an FMRI study. European Journal of Neuroscience, 19, 741–54.
Malhi, G., Lagopoulos, J., Sachdev, P. et al. (2004b). Cognitive generation of affect in hypomania: an fMRI study. Bipolar Disorders, 6, 271–85.
Malhi, G. S., Lagopoulos, J., Owen, A. M. and Yatham, L. N. (2004c). Bipolaroids: functional imaging in bipolar disorder. Acta Psychiatrica Scandinavica, 422, 46–54.
Malhi, G. S., Lagopoulos, J., Owen, A., Ivanovski, B. and Sachdev, P. (2007a). Reduced activation to implicit affect induction in euthymic bipolar patients: an fMRI study. Journal of Affective Disorders, 97, 109–22.
Malhi, G. S., Lagopoulos, J., Sachdev, P. et al. (2007b). Is a lack of disgust something to fear? An fMRI facial emotion recognition study in euthymic bipolar disorder patients. Bipolar Disorders, 9, 345–57.
Malhi, G. S., Ivanovski, B., Hadzi-Pavlovic, D. et al. (2007c). Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disorders, 9, 114–25.
Malhi, G. S., Ivanovski, B., Wen, W. et al. (2007d). Measuring mania metabolites: a longitudinal protonspectroscopy study of hypomania. Acta Psychiatrica Scandinavica, 116(Suppl.434), 57–66.
McDonald, C., Zanelli, J., Rabe-Hesketh, S. et al. (2004). Meta-analysis of magnetic resonance imaging brain morphometry studies in bipolar disorder. Biological Psychiatry, 56, 411–17.
McGuffin, P., Rijsdijk, F., Andrew, M. et al. (2003). The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Archives of General Psychiatry, 60, 497–502.
McQueen, M. B., Devlin, B., Faraone, S. V. et al. (2005). Combined analysis from 11 linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosome q and 8q. American Journal of Human Genetics, 77, 582–95.
Moore, G., Bebchuk, J., Parrish, J. et al. (1999). Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. American Journal of Psychiatry, 156, 1902–8.
Olley, A., Malhi, G. S., Mitchell, P. et al. (2005). When euthymia is just not good enough: The neuropsychology of bipolar disorder. Journal of Nervous and Mental Disease, 193, 323–30.
Pandey, G., Dwivedi, Y., Kumari, R. and Janicak, P. G. (1998). Protein kinase C in platelets of depressed patients. Biological Psychiatry, 44, 909–11.
Redmond, A. and Leonard, B. (1998). An evaluation of the role of the noradrenergic system in the neurobiology of depression: a review. Biological Psychiatry, 46, 247–55.
Rubinzstein, J., Fletcher, P., Rogers, R. et al. (2001). Decision-making in mania: A PET study. Brain, 124, 2550–63.
Sassi, R., Nicoletti, J., Brambilla, P. et al. (2001). Decreased pituitary volume in patients with bipolar disorder. Biological Psychiatry, 50, 271–80.
Schildraut, J., Orsulak, P., Schatzberg, A. et al. (1978). Toward a biochemical classification of depressive disorders. I. Differences in urinary excretion of MHPG and other catecholamine metabolites in clinically defined subtypes of depression. Archives of General Psychiatry, 35, 1427–33.
Shiah, I-S., Ko, H-C., Lee, J-F. and Lu, R-B. (1999). Platelet 5-HT and plasma MHPG levels in patients with Bipolar I and Bipolar II depression and normal control subjects. Journal of Affective Disorders, 52, 101–10.
Strakowski, S., Adler, C., Holland, S., Mills, N. and DeBello, M. (2004). A preliminary fMRI study of substained attention in euthymic, unmedicated bipolar disorder. Neuropsychopharmacology, 29, 1734–40.
Summers, M., Papdopoulou, K., Bruno, S., Cipolotti, L. and Ron, M. A. (2006). Bipolar I and Bipolar II disorder: cognition and emotion processing. Psychological Medicine, 36, 1799–809.
Wang, H-Y., and Friedman, E. (1996). Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biological Psychiatry, 40, 568–75.
Wang, H-Y., Markowitz, P., Levinson, D., Undie, A. and Friedman, E. (1999). Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. Journal of Psychiatric Research, 33, 171–9.
Wasserman, M., Corson, T., Sibony, D. et al. (2004). Chronic lithium treatment attenuates intracellular calcium mobilization. Neuropsychopharmacology, 29, 759–69.
Yamawaki, S., Kagaya, A., Tawara, Y. and Inagaki, M. (1998). Extracellular calcium signaling systems in the pathophysiology of affective disorders. Life Sciences, 62, 1665–70.
Yatham, L. N. and Malhi, G. S. (2003). Neurochemical brain imaging studies in bipolar disorder. Acta Neuropsychiatry, 15, 381–7.
Yildiz-Yesiloglu, A. and Ankerst, D. P. (2006). Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Progress in Neuropsychopharmacology and Biological Psychiatry, 30, 969–95.

Reference Title: REFERENCES

Reference Type: reference-list

Altshuler, L. L., Suppes, T., Black, D. et al. (2003). Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at one-year follow-up. American Journal of Psychiatry, 160, 1252–62.
Altshuler, L. L., Suppes, T., Black, D. O. et al. (2006). Lower switch rate in depressed patients with Bipolar II than Bipolar I Disorder treated adjunctively with second-generation antidepressants. American Journal of Psychiatry, 163, 313–15.
Amsterdam, J. D. and Brunswick, D. J. (2003). Antidepressant monotherapy for Bipolar Type II major depression. Journal of Affective Disorders, 5, 388–95.
Amsterdam, J. D. and Shults, J. (2005a). Fluoxetine monotherapy of Bipolar II and Bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. International Clinical Psychopharmacology, 20, 257–64.
Amsterdam, J. D. and Shults, J. (2005b). Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of Bipolar Type I and Type II major depression – lack of manic induction. Journal of Affective Disorders, 87, 121–30.
Amsterdam, J. D., Shults, J., Brunswick, D. J. and Hundert, M. (2004). Short-term fluoxetine monotherapy for Bipolar Type II or Bipolar NOS major depression – low manic switch rate. Bipolar Disorders, 6, 75–81.
Bauer, M. S., Wisniewski, S. R., Marangell, L. B. et al. for the STEP-BD Investigators (2006). Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Journal of Clinical Psychiatry, 67, 48–55.
Frye, M. A., Grunze, H., Suppes, T. et al. (2005). Modafinil in the treatment of bipolar depression: a placebo-controlled trial. New research abstract presented at the ACNP Annual Meeting, 11–15 December, Hilton Waikoloa Village, Hawaii.
Ghaemi, S. N., Rosenquist, K. J., Ko, J. Y. et al. (2004). Antidepressant treatment in bipolar versus unipolar depression. American Journal of Psychiatry, 161, 163–5.
Goldberg, J. F., Burdick, K. E. and Endick, C. J. (2004). Preliminary randomized, double-blind, placebo-controlled trial of pramipexole for treatment-resistant bipolar depression. American Journal of Psychiatry, 161, 564–6.
Goldberg, J. F. and Truman, C. J. (2003). Antidepressant-induced mania: An overview of current controversies. Bipolar Disorders, 5, 407–20.
Goldberg, J. F. and Whiteside, J. E. (2002). The association between substance abuse and antidepressant-induced mania in bipolar disorder: A preliminary study. Journal of Clinical Psychiatry, 63, 791–5.
Himmelhoch, J. M., Thase, M. E., Mallinger, A. G. and Houck, P. (1991). Tranylcypromine versus imipramine in anergic bipolar depression. American Journal of Psychiatry, 148, 910–16.
Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of Bipolar II Disorder. Archives of General Psychiatry, 60, 261–9.
Leverich, G. S., Altshuler, L. L., Frye, M. A. et al. (2006). Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. American Journal of Psychiatry, 163, 232–9.
MacQueen, G. M., Young, L. T., Marriott, M. et al. (2002). Previous mood state predicts response and switch rates in patients with bipolar depression. Acta Psychiatrica Scandinavica, 105, 414–18.
Manwani, S. G., Pardo, T. B., Albanese, M. J. et al. (2006). Substance use disorder and other predictors of antidepressant-induced mania: a retrospective chart review. Journal of Clinical Psychiatry, 67, 1341–5.
Moller, H. J., Bottlender, R., Grunze, H., Strauss, A. and Wittmann, J. (2001). Are antidepressants less effective in the acute treatment of Bipolar I compared to unipolar depression. Journal of Affective Disorders, 67, 141–6.
Nemeroff, C. B., Evans, D. L., Gyulai, L. et al. (2001). Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. American Journal of Psychiatry, 158, 906–12.
Parker, G., Tully, L., Olley, A. and Hadzi-Pavlovic, D. (2006). SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of Affective Disorders, 92, 205–14.
Peet, M. (1994). Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. British Journal of Psychiatry, 164, 549–50.
Post, R. M., Altshuler, L. L., Leverich, G. S. et al. (2006). Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. British Journal of Psychiatry, 189, 124–31.
Prien, R. F., Himmelhoch, J. M. and Kupfer, D. J. (1988). Treatment of mixed mania. Journal of Affective Disorders, 15, 9–15.
Rihmer, Z. and Pestality, P. (1999). Bipolar II disorder and suicidal behavior. Psychiatry Clinics of North America, 22, 667–73.
Vieta, E., Martinez-Aran, A., Goikolea, J. M. et al. (2002). A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Journal of Clinical Psychiatry, 63, 508–12.
Wehr, T. A., Sack, D. A., Rosenthal, N. E and Cowdry, R. W. (1988). Rapid-cycling affective disorder: contributing factors and treatment responses in 51 patients. American Journal of Psychiatry, 145, 179–84.
Young, L. T., Joffe, R. T., Robb, J. C. et al. (2000). Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. American Journal of Psychiatry, 157, 124–6.
Zarate, C. A. Jr., Payne, J. L., Singh, J. et al. (2004). Pramipexole for Bipolar II depression: A placebo-controlled proof of concept study. Biological Psychiatry, 56, 54–60.

Reference Title: REFERENCES

Reference Type: reference-list

Amsterdam, J. D. and Brunswick, D. J. (2003). Antidepressant monotherapy for Bipolar Type II major depression. Bipolar Disorders, 5, 388–95.
Beck, A. T., Ward, C. H., Mendelson, M., Mock, J. and Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4, 561–71.
Gijsman, H. J., Geddes, J. R., Rendell, J. M., Nolen, W. A. and Goodwin, G. M. (2004). Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. American Journal of Psychiatry, 61, 1537–47.
Goodwin, G. M. (2003). Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 17, 149–73.
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56–62.
Parker, G. (2002). Do the newer antidepressants have mood stabilizing properties? (letter). Australian and New Zealand Journal of Psychiatry, 36, 427–8.
Parker, G. and Parker, K. (2003). Which antidepressants flick the switch? Australian and New Zealand Journal of Psychiatry, 37, 464–8.
Parker, G., Tully, L., Olley, A. and Hadzi-Pavlovic, D. (2006). SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of Affective Disorders, 92, 205–14.
Parker, G., Tully, A., Olley, A. and Barnes, C. (2007). The validity and utility of patient's daily ratings of mood and impairment in clinical trials of bipolar disorder. Acta Psychiatrica Scandinavica (in press).
Peet, M. (1994). Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. British Journal of Psychiatry, 164, 549–50.
Young, R. C., Biggs, J. T., Ziegler, V. E. and Meyer, D. A. (1978). A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry, 133, 429–35.

Reference Title: REFERENCES

Reference Type: reference-list

Baldessarini, R. J. and Tondo, L. (2000). Does lithium therapy still work? Evidence of stable responses over three decades. Archives of General Psychiatry, 57, 187–90.
Baldessarini, R. J., Tondo, L., Floris, G. and Hennen, J. (1998). Effects of rapid cycling on response to lithium maintenance treatment in 360 Bipolar I and II disorder patients. Journal of Affective Disorders, 155, 1434–6.
Baldessarini, R. J., Tondo, L. and Hennen, J. (2001). Treating the suicidal patient with bipolar disorder: reducing suicide risk with lithium. Annals of the New York Academy of Sciences, 932, 24–38.
Bauer, M. S. and Mitchner, L. (2004). What is a ‘mood stabilizer’? An evidence-based response. American Journal of Psychiatry, 161, 3–18.
Brown, E. S. (2005). Bipolar disorder and substance abuse. Psychiatric Clinics of North America, 28, 415–25.
Brown, E. S., Nejtek, V. A., Perantie, D. C., Orsulak, P. J. and Bobadilla, L. (2003). Lamotrigine in patients with bipolar disorder and cocaine dependence. Journal of Clinical Psychiatry, 64, 197–201.
Calabrese, J. R., Bowden, C. L., McElroy, S. L. et al. (1999). Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. American Journal of Psychiatry, 156, 1019–23.
Calabrese, J. R., Shelton, M. D., Rapport, D. J. et al. (2005). A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. American Journal of Psychiatry, 162, 2152–61.
Calabrese, J. R., Suppes, T., Bowden, C. L. et al. (2000). A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. Journal of Clinical Psychiatry, 61, 841–50.
Carney, S. M. and Goodwin, G. M. (2005). Lithium – a continuing story in the treatment of bipolar disorder. Acta Psychiatrica Scandinavica, 111 (Suppl. 426), S7–12.
Dunner, D. L., Stallone, F. and Fieve, R. R. (1982). Prophylaxis with lithium carbonate: an update. Archives of General Psychiatry, 39, 1344–5.
Fieve, R. R., Kumbaraci, T. and Dunner, D. L. (1976). Lithium prophylaxis of depression in Bipolar I, Bipolar II, and unipolar patients. American Journal of Psychiatry, 133, 925–9.
Frankenburg, F. R. and Zanarini, M. C. (2002). Divalproex sodium treatment of women with Borderline Personality Disorder and Bipolar II: a double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry, 63, 442–6.
Frye, M. A., Ketter, T. A., Kimbrell, T. A. et al. (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology, 20, 607–14.
Ghaemi, S. N. and Goodwin, F. K. (2001). Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. Journal of Affective Disorders, 65, 167–71.
Ghaemi, S. N., Katzow, J. J., Desai, S. P. and Goodwin, F. K. (1998). Gabapentin treatment of mood disorders: a preliminary study. Journal of Clinical Psychiatry, 59, 426–9.
Ghaemi, S. N., Hsu, D. J., Thase, M. et al. (2006a). Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatric Services, 57, 660–5.
Ghaemi, S. N., Schrauwen, E., Klugman, J. et al. (2006b). Long-term lamotrigine plus lithium for bipolar disorder: one year outcome. Journal of Psychiatric Practice, 12, 300–5.
GlaxoSmithKline (2006). A multicenter, double-blind, placebo-controlled, fixed-dose, eight-week evaluation of the efficacy and safety of lamotrigine in the treatment of major depression in patients with Type II bipolar disorder. http://ctr.gsk.co.uk.
Goodwin, F. K., Fireman, B., Simon, G. E. et al. (2003). Suicide risk in bipolar disorder during treatment with lithium and divalproex. Journal of the American Medical Association, 290, 1467–73.
Greil, W. and Kleindienst, N. (1999). Lithium versus carbamazepine in the maintenance treatment of Bipolar II Disorder and Bipolar Disorder Not Otherwise Specified. International Clinical Psychopharmacology, 14, 283–5.
Hadjipavlou, G. H. and Yatham, L. (2004). Bipolar II Disorder: an overview of recent developments. Canadian Journal of Psychiatry, 49, 802–12.
Jacobsen, F. M. (1993). Low-dose valproate: a new treatment for cyclothymia, mild rapid-cycling disorders, and premenstrual syndrome. Journal of Clinical Psychiatry, 54, 229–34.
Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of Bipolar II Disorder. Archives of General Psychiatry, 60, 261–9.
Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2005). Psychosocial disability in the course of Bipolar I and II Disorders. A prospective, comparative, longitudinal study. Archives of General Psychiatry, 62, 1322–30.
Kane, J. M., Quitkin, F. M., Rifkin, A. et al. (1982). Lithium carbonate and imipramine in the prophylaxis of unipolar and Bipolar II illness: a prospective, placebo-controlled comparison. Archives of General Psychiatry, 39, 1065–9.
Kleindienst, N. and Greil, W. (2000). Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology, 42 (Suppl. 1), S2–10.
Malhi, G. S., Mitchell, P. B., Berk, M. and Goodwin, G. M. (2005). Mood stabilizers: a labile label. Acta Psychiatrica Scandinavica, 111 (Suppl. 426), S5–6.
Margolese, H. C., Beauclair, L., Szkrumelak, N. and Chouinard, G. (2003). Hypomania induced by adjunctive lamotrigine. American Journal of Psychiatry, 160, 183–4.
McIntyre, R. S., Mancini, D. A., McCann, S. et al. (2002). Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disorders, 4, 207–13.
McIntyre, R. S., Riccardelli, R. and Binder, C. (2005). Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Canadian Journal of Psychiatry, 50, 415–22.
National Institute for Health and Clinical Excellence (NICE) (2006). Bipolar disorder. NICE clinical guideline 38. http://www.nice.org.uk.
Nemeroff, C. B., Evans, D. L., Gyulai, L. et al. (2001). Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. American Journal of Psychiatry, 158, 906–12.
Nierenberg, A. A., Ostacher, M. J., Calabrese, J. R. et al. and STEP-BD Investigators (2006). Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. American Journal of Psychiatry, 163, 210–16.
Quitkin, F., Rifkin, A., Kane, J., Ramos-Lorenzi, J. R. and Klein, D. F. (1978). Prophylactic effect of lithium and imipramine in unipolar and Bipolar II patients: a preliminary report. American Journal of Psychiatry, 135, 570–2.
Rubio, G., Lopez-Munoz, F. and Alamo, C. (2006). Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disorders, 8, 289–93.
Schaffer, A., Zuker, P. and Levitt, A. (2006). Randomised, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. Journal of Affective Disorders, 96, 95–9.
Suppes, T., Brown, E. S., McElroy, S. L. et al. (1999). Lamotrigine for the treatment of bipolar disorder: a clinical case series. Journal of Affective Disorders, 53, 95–8.
Thase, M. (2005). Bipolar depression: issues in diagnosis and treatment. Harvard Review of Psychiatry, 13, 257–71.
Tondo, L., Baldessarini, R. J. and Floris, G. (2001). Long-term clinical effectiveness of lithium maintenance treatment in Types I and II bipolar disorders. British Journal of Psychiatry, 41 (Suppl. 178), S184–90.
Tondo, L., Baldessarini, R. J., Hennen, J. and Floris, G. (1998). Lithium maintenance treatment of depression and mania in Bipolar I and Bipolar II disorders. American Journal of Psychiatry, 155, 638–45.
van der Loos, M., Nolen, W. A. and Vieta, E. (2006). Lamotrigine as add-on to lithium in bipolar depression. Paper presented at the fifth European Stanley Conference on Bipolar Disorder, Barcelona, 5–7 October.
Vieta, E., Sanchez-Moreno, J., Goikolea, J. M. et al. (2003). Adjunctive topiramate in Bipolar II Disorder. World Journal of Biological Psychiatry, 4, 172–6.
Vieta, E., Goikolea, J. M., Martinez-Aran, A. et al. (2006). A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. Journal of Clinical Psychiatry, 67, 473–7.
Winsberg, M. E., DeGolia, S. G., Strong, C. M. and Ketter, T. A. (2001). Divalproex therapy in medication-naïve and mood-stabilizer-naïve Bipolar II depression. Journal of Affective Disorders, 67, 207–12.
Yatham, L. (2004). Diagnosis and management of patients with Bipolar II Disorder. Journal of Clinical Psychiatry, 66 (Suppl. 1), S13–17.
Yatham, L. N., Kennedy, S. H., O'Donovan, C. et al. (2005). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disorders, 7 (Suppl. 3), S5–69.
Young, L. T., Robb, J. C., Hasey, G. M. et al. (1999). Gabapentin as an adjunctive treatment in bipolar disorder. Journal of Affective Disorders, 55, 73–7.
Young, L. T., Joffe, R. T. and Robb, J. C. (2000). Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. American Journal of Psychiatry, 157, 124–6.

Reference Title: REFERENCES

Reference Type: reference-list

Altshuler, L. L., Post, R. M., Leverich, G. S. et al. (1995). Antidepressant-induced mania and cycle acceleration: a controversy revisited. American Journal of Psychiatry, 152, 1130–8.
Amsterdam, J. D. and Shults, J. (2005). Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of Bipolar Type I and Type II major depression – lack of manic induction. Journal of Affective Disorders, 87, 121–30.
Berk, M. and Dodd, S. (2005). Efficacy of atypical antipsychotics in bipolar disorder. Drugs, 65, 257–69.
Bowden, C. L. (2005). Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. Journal of Clinical Psychiatry, 66 (Suppl. 3), S12–19.
Brown, E. B., McElroy, S.L., Keck, P. E. Jr. et al. (2006). A seven-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of Bipolar I depression. Journal of Clinical Psychiatry, 67, 1025–33.
Brugue, E. and Vieta, E. (2007). Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Progress in Neuropsychopharmacological and Biological Psychiatry, 31, 275–82.
Dunner, D. (1979). Rapid-cycling manic depressive illness. Psychiatric Clinics of North America, 2, 461–7.
El-Mallakh, R., Weisler, R. H., Townsend, M. H. and Ginsberg, L. D. (2006). Bipolar II Disorder: current and future treatment options. Annals of Clinical Psychiatry, 18, 259–66.
García-Amador, M., Pacchiarotti, I., Valenti, M. et al. (2006). Role of aripiprazole in treating mood disorders. Expert Review of Neurotherapeutics, 6, 1777–83.
Ghaemi, S. N., Boiman, E. E. and Goodwin, F. K. (2000). Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. Journal of Clinical Psychiatry, 61, 804–8.
Ghaemi, N. S., Hsu, D. J., Soldani, F. and Goodwin, F. K. (2003). Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders, 5, 421–33.
Hadjipavlou, G., Mok, H. and Yatham, L. N. (2004). Pharmacotherapy of Bipolar II Disorder: a critical review of current evidence. Bipolar Disorders, 6, 14–25.
Hirschfeld, R. M. A. (2004). Bipolar depression: the real challenge. European Neuropsychopharmacology, 14, 83–8.
Hirschfeld, R. M., Weisler, R. H., Raines, S. R. and Macfadden, W. for the BOLDER Study Group (2006). Quetiapine in the treatment of anxiety in patients with Bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 67, 355–62.
Judd, L. L., Akiskal, H. S., Schetter, P. J. et al. (2002). The long-term natural history of the weekly symptomatic status of Bipolar I Disorder. Archives of General Psychiatry, 59, 530–7.
Kupka, R. W., Luckenbaugh, D. A., Post, R. M., Leverich, G. S. and Nolen, W. A. (2003). Rapid- and non-rapid-cycling bipolar disorder: A meta-analysis of clinical studies. Journal of Clinical Psychiatry, 64, 1483–94.
Kuyler, P. L. (1988). Rapid-cycling Bipolar II illness in three closely related individuals. American Journal of Psychiatry, 145, 114–15.
McIntyre, R. S., Mancini, D. A., Srinivasan, J. et al. (2004). The antidepressant effects of risperidone and olanzapine in bipolar disorder. Canadian Journal of Clinical Pharmacology, 11, e218–26. Epub., October 4.
Milev, R., Abraham, G. and Zaheer, J. (2006). Add-on quetiapine for bipolar depression: a 12-month open-label trial. Canadian Journal of Psychiatry, 51, 523–30.
Muzina, D. J. and Calabrese, J. R. (2005). Maintenance therapies in bipolar disorder: focus on randomised controlled trials. Australian and New Zealand Journal of Psychiatry, 39, 652–61.
Reinares, M., Martinez-Aran, A., Colom, F. et al. (2000). Long-term effects of the treatment with risperidone versus conventional neuroleptics on the neuropsychological performance of euthymic bipolar patients. Actas Españolas de Psiquiatría, 28, 231–8.
Suppes, T., Hirschfeld, R.M., Vieta, E. et al. (2006). Quetiapine monotherapy for depressive episodes in Bipolar II Disorder: combined results from two placebo-controlled studies. Bipolar Disorders, 8 (Suppl. 1), S34–5.
Tohen, M., Vieta, E., Calabrese, J. et al. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of Bipolar I depression. Archives of General Psychiatry, 60, 1079–88.
Torrent, C., Martinez-Aran, A., Daban, C. et al. (2006). Cognitive impairment in Bipolar II Disorder. British Journal of Psychiatry, 189, 254–9.
Vieta, E. (2003). Atypical antipsychotics in the treatment of mood disorders. Current Opinion in Psychiatry, 16, 23–7.
Vieta, E. (2007). Managing Bipolar Disorder in Clinical Practice. London: Current Medicine Group.
Vieta, E. and Goikolea, J. M. (2005). Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disorders, 7 (Suppl. 2), S1–S13.
Vieta, E., Gastó, C., Otero, A., Nieto, E. and Vallejo, J. (1997). Differential features between Bipolar I and Bipolar II disorder. Comprehensive Psychiatry, 38, 98–101.
Vieta, E., Gasto, C., Colom, F. et al. (2001). Role of risperidone in Bipolar II: an open six-month study. Journal of Affective Disorders, 67, 213–19.
World Health Organization (2001). World Health Report: Mental Health: New Understanding, New Hope. Geneva: World Health Organization.
Yatham, L. N., Goldstein, J. M., Vieta, E. et al. (2005). Atypical antipsychotics in bipolar depression: potential mechanisms of action. Journal of Clinical Psychiatry, 66, 40–8.
Yatham, L. N., Kennedy, S. H., O'Donovan, C. et al. (2006). Guidelines Group, CANMAT. Canadian Network for Mood and Anxiety Treatments guidelines for the management of patients with bipolar disorder: Update 2007. Bipolar Disorders, 8, 721–39.
Yatham, L. N., Kennedy, S. H., O'Donovan, C. et al. (2005). CANMAT. Canadian Network for Mood and Anxiety Treatments guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders, 7 (Suppl. 3), S5–69.

Reference Title: REFERENCES

Reference Type: reference-list

Chiu, C. C., Huang, S. Y., Chen, C. C. and Su, K. P. (2005). Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with Bipolar I Disorder. (Letter to the Editor.) Journal of Clinical Psychiatry, 66, 1613–14.
Chiu, C. C., Huang, S. Y., Su, K. P. et al. (2003). Polyunsaturated fatty acid deficit in patients with bipolar mania. European Neuropsychopharmacology, 13, 99–103.
Edwards, R., Peet, M., Shay, J. and Horrobin, D. (1998). Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. Journal of Affective Disorders, 48, 149–55.
Frangou, S., Lewis, M. and McCrone, P. (2006). Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. British Journal of Psychiatry, 188, 46–50.
Hibbeln, J. R. (1998). Fish consumption and major depression. Lancet, 351, 1213.
Hirashima, F., Parow, A., Stoll, A. et al. (2004). Omega-3 fatty acid treatment and T2 whole brain relaxation times in bipolar disorder. American Journal of Psychiatry, 161, 1922–4.
Keck, P. E. Jr, Freeman, M. P., McElroy, S. L. et al. (2002). A double-blind, placebo-controlled trial of eicosapentaenoic acid in rapid-cycling bipolar disorder. Bipolar Disorders, 4, 26–7.
Keck, P. E. Jr, McElroy, S. L., Mintz, J. et al. (2006). Double-blind, placebo-controlled trials of ethyl-eicosapentaenoate in the treatment of bipolar depression and rapid-cycling bipolar disorder. Biological Psychiatry, 60, 1020–2.
Kinrys, G. (2000). Are omega-3 fatty acids beneficial in depression but not mania? In reply. Archives of General Psychiatry, 57, 716–17.
Logan, A. C. (2003). Neurobehavioural aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Alternative Medicine Review, 8, 410–25.
Maes, M., Christophe, A., Delanghe, J. et al. (1999). Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Research, 85, 275–91.
Marangell, L. B., Suppes, T., Ketter, T. A. et al. (2006). Omega-3 fatty acids in bipolar disorder: clinical and research considerations. Prostaglandins, Leukotrienes and Essential Fatty Acids, 75, 315–21.
Noaghuil, S. and Hibbeln, J. R. (2003). Cross-national comparisons of seafood consumption and rates of bipolar disorders. American Journal of Psychiatry, 160, 2222–7.
Osher, Y., Bersudsky, Y. and Belmaker, R. H. (2005). Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. Journal of Clinical Psychiatry, 66, 726–9.
Parker, G., Gibson, N., Brotchie, H., Heruc, G., Rees A-M. and Hadzi-Pavlovic, D. (2006). Omega-3 fatty acids and mood disorders. American Journal of Psychiatry, 163, 969–78.
Peet, M., Murphy, B., Shay, J. and Horrobin, D. (1998). Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biological Psychiatry, 43, 315–19.
Rapoport, S. I. and Bosetti, F. (2002). Do lithium and the anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Archives of General Psychiatry, 59, 592–6.
Sampath, H. and Ntambi, J. M. (2004). Polyunsaturated fatty acid regulation of gene expression. Nutrition Review, 62, 333–9.
Stoll, A. L., Damico, K. E., Marangell, L. B. and Severus, W. E. (2000). Reply to Su, K-P., Shen W. W., Huang S-Y.: Are omega-3 fatty acids beneficial in depression but not mania? (letter). Archives of General Psychiatry, 57, 716–17.
Stoll, A. L., Locke, L. B., Marangell, L. B. and Severus, W. E. (1999a). Omega-3 fatty acids and bipolar disorder: a review. Prostaglandins, Leukotrienes and Essential Fatty Acids, 60, 329–37.
Stoll, A. L., Severus, W. E., Freeman, M. P. et al. (1999b). Omega-3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Archives of General Psychiatry, 56, 407–12.

Reference Title: REFERENCES

Reference Type: reference-list

American Psychiatric Association (2002). Practice Guidelines for the Treatment of Patients with Bipolar Disorder (revision). American Journal of Psychiatry, 159 (Suppl. 4), S1–50.
Aschoff, J. (1981). Handbook of Behavioural Neurobiology. Vol. 4. Biological Rhythms. New York: Plenum Press.
Ball, J., Mitchell, P., Corry, J., Skillecorn, A. M. S. and Malhi, G. S. (2006). A randomised controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. Journal of Clinical Psychiatry, 67, 277–86.
Clarkin, J. F., Carpenter, D., Hull, J., Wilner, P. and Glick, I. (1998). Effects of psychoeducation for married patients with bipolar disorder and their spouses. Psychiatric Services, 49, 531–3.
Cochran, S. (1984). Preventing medication non-compliance in the outpatient treatment of bipolar affective disorder. Journal of Consulting and Clinical Psychology, 52, 873–8.
Colom, F., Vieta, E., Martinez-Aran, A. et al. (2003). A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Archives of General Psychiatry, 60, 402–7.
Frank, E., Kupfer, D. J., Thase, M. E. et al. (2005). Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar disorder. Archives of General Psychiatry, 62, 996–1003.
Frank, E. and Swartz, H. (2004). Interpersonal and social rhythm. In Psychological Treatment of Bipolar Disorder, ed. S. L. Johnson and R. L. Leahy. New York: The Guilford Press.
Frank, E., Swartz, H., Mallinger, A. et al. (1999). Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. Journal of Abnormal Psychology, 108, 579–87.
Glick, I. D., Burti, L., Okonogi, K. and Sacks, M. (1994). Effectiveness in psychiatric care: psychoeducational outcome for patients with major affective disorder and their families. British Journal of Psychiatry, 164, 104–6.
Goodwin, F. K. and Jamison, K. R. (1990). Manic-Depressive Illness. New York: Oxford University Press.
Goodwin, G. and Sachs, G. (2004). Fast Facts – Bipolar Disorder. Oxford: Health Press Limited.
Lam, D. H., Bright, J., Jones, S. et al. (2000). Cognitive therapy for bipolar illness: a pilot study of relapse prevention. Cognitive Therapy and Research, 24, 503–20.
Lam, D., Watkins, E., Hayward, P. et al. (2003). A randomised controlled study of cognitive therapy of relapse prevention for bipolar affective disorder: outcome of the first year. Archives of General Psychiatry, 60, 145–52.
Miklowitz, D. J. (2004). Family therapy. In Psychological Treatment of Bipolar Disorder, ed. S. L. Johnson and R. L. Leahy. New York: The Guilford Press.
Miklowitz, D. J., Goldstein, M. J., Nuechterlein, K. H., Snyder, K. S. and Mintz, J. (1988). Family factors and the course of bipolar affective disorder. Archives of General Psychiatry, 45, 225–31.
Miklowitz, D. J., Goldstein, M. J., Doane, J. A. et al. (1989). Is expressed emotion an index of a transactional process? I. Parents' affective style. Family Process, 28, 153–67.
Miklowitz, D. J., Simoneau, T., George, E. et al. (2000). Family focused treatment of bipolar disorder: one-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biological Psychiatry, 48, 582–92.
Miklowitz, D. J, George, E. L., Richards, J. A., Simoneau, T. L. and Suddath, R. L. (2003). A randomised study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Archives of General Psychiatry, 60, 904–12.
Mitchell, P. B., Malhi, G. and Ball, J. R. (2004). Major advances in bipolar disorder. Medical Journal of Australia, 181, 207–10.
Newman, C. F. (2004). Suicidality. In Psychological Treatment of Bipolar Disorder, ed. S. L. Johnson and R. L. Leahy. New York: Guilford Press.
O'Connell, R. A., Mayo, J. A., Flatow, L., Cuthbertson, B. and O'Brien, B. E. (1991). Outcome of bipolar disorder on long-term treatment with lithium. British Journal of Psychiatry, 159, 123–9.
Parker, G. (2004). Highlighting Bipolar II Disorder. Canadian Journal of Psychiatry, 49, 791–3.
Perry, A., Tarrier, N., Morriss, R., McCarthy, E. and Limb, K. (1999). Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. British Medical Journal, 318, 149–53.
Rihmer, Z. and Kiss, K. (2002). Bipolar disorders and suicide behaviour. Bipolar Disorder, 4, 21–5.
Scott, J., Garland, A. and Moorhead, S. (2001). A pilot study of cognitive therapy in bipolar disorders. Psychological Medicine, 31, 459–67.
Scott, J., Paykel, E., Morriss, R., Bentall, R. et al. (2006). Cognitive-behaviour therapy for bipolar disorder. British Journal of Psychiatry, 188, 313–20.
Simoneau, T. L., Miklowitz, D. J. and Saleem, R. (1998). Expressed emotion and interactional patterns in the families of bipolar patients. Journal of Abnormal Psychology, 107, 497–507.
Van Gent, E. and Zwart, F. (1991). Psychoeducation of partners of bipolar manic patients. Journal of Affective Disorders, 21, 15–18.
Van Gent, E. and Zwart, F. (1993). Ultra-short versus short group therapy in addition to lithium. Patient Education and Counselling, 21, 135–41.
Van Gent, E., Vida, S. and Zwart, F. (1988). Group therapy in addition to lithium in patients with bipolar disorders. Acta Psychiatrica Belgica, 88, 405–18.
Vaughn, C. E. and Leff, J. P. (1976). The influence of family and social factors on the course of psychiatric illness: a comparison of schizophrenic and depressed neurotic patients. British Journal of Psychiatry, 129, 125–37.

Reference Title: REFERENCES

Reference Type: reference-list

Kabat-Zinn, J. (1990). Full Catastrophe Living: Using the Wisdom of your Body and Mind to Face Stress, Pain and Illness. New York: Delta.
Miklowitz, D. J. (2002). The Bipolar Disorder Survival Guide: What You and your Family need to Know. London: Guilford Press.
Miller, W. R. and Rollnick, S. (1991). Motivational Interviewing: Preparing People to change Addictive Behavior. New York: Guilford Press.
Russell, S. (2005). A Lifelong Journey: Staying well with Manic Depression/Bipolar Disorder. Melbourne: Michelle Anderson Publishing.
Russell, S. J. and Browne, J. L. (2005). Staying well with bipolar disorder. Australian and New Zealand Journal of Psychiatry, 39, 187–93.
Segal, Z. V., Williams, J. M. G. and Teasdale, J. D. (2002). Mindfulness-based Cognitive Therapy for Depression. New York: Guilford Press.
Seligman, M. E. P. (2002). Authentic Happiness. New York: Free Press.

Reference Title: REFERENCES

Reference Type: reference-list

Bratfos, O. and Haug, J. O. (1968). The course of manic–depressive psychosis. A follow-up investigation of 215 patients. Acta Psychiatrica Scandinavica, 44, 89–112.
Shobe, F. O. and Brion, P. (1971). Long-term prognosis in manic-depressive illness: a follow-up investigation of 111 patients. Archives of General Psychiatry, 24, 334–7.

Reference Title: REFERENCES

Reference Type: reference-list

Jamison, K. (1995). An Unquiet Mind: A Memoir of Moods and Madness. New York: Alfred A. Knopf.
Parker, G. (2002). Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders. Journal of Clinical Psychopharmacology, 17, 87–9.
Parker, G. and Malhi, G. (2001). Are atypical antidepressant drugs also atypical antidepressants? Australian and New Zealand Journal of Psychiatry, 35, 677–83.
Parker, G., Brotchie, H. and Parker, K. (2005). Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? American Journal of Psychiatry, 162, 796–8.
Wigney, T., Eyers, K. and Parker, G. (2007). Journeys with the Black Dog. Inspirational Stories of Bringing Depression to Heel. Sydney: Allen & Unwin.

Reference Title: REFERENCES

Reference Type: reference-list

American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM–IV–TR). Washington. DC: American Psychiatric Association.
Amsterdam, J. (1998). Efficacy and safety of venlafaxine in the treatment of Bipolar II major depressive episode. Journal of Clinical Psychopharmacology, 18, 414–17.
Amsterdam, J. D. and Brunswick, D. J. (2003). Antidepressant monotherapy for Bipolar Type II major depression. Bipolar Disorders, 5, 388–95.
Amsterdam, J. D. and Garcia-Espana, F. (2000). Venlafaxine monotherapy in women with Bipolar II and unipolar major depression. Journal of Affective Disorders, 59, 225–9.
Amsterdam, J. D., Garcia-Espana, F., Fawcett, J. et al. (1998). Efficacy and safety of fluoxetine in treating Bipolar II major depressive episode. Journal of Clinical Psychopharmacology, 18, 435–40.
Amsterdam, J. D., Shults, J., Brunswick, D. J. and Hundert, M. (2004). Short-term fluoxetine monotherapy for Bipolar Type II or Bipolar NOS major depression – low manic switch rate. Bipolar Disorders, 6, 75–81.
Baron, M., Gershon, E. S., Rudy, V., Jonas, W. Z. and Buchsbaum, M. (1975). Lithium carbonate response in depression. Prediction by unipolar/bipolar illness, average-evoked response, catechol-O-methyl transferase, and family history. Archives of General Psychiatry, 32, 1107–11.
Bowden, C. L., Grunze, H., Mullen, J. et al. (2005). A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Journal of Clinical Psychiatry, 66, 111–21.
Brown, E. B., McElroy, S. L., Keck, P. E. Jr. et al. (2006). A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of Bipolar I depression. Journal of Clinical Psychiatry, 67, 1025–33.
Calabrese, J. R., Keck, P. E. Jr., Macfadden, W. et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of Bipolar I or II depression. American Journal of Psychiatry, 162, 1351–60.
Calabrese, J. R., Suppes, T., Bowden, C. L. et al. (2000). Lamictal 614 Study Group. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Journal of Clinical Psychiatry, 61, 841–50.
Colom, F., Vieta, E., Martinez-Aran, A. et al. (2003). A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Archives of General Psychiatry, 60, 402–7.
Dunner, D. L., Stallone, F. and Fieve, R. R. (1976). Lithium carbonate and affective disorders. A double-blind study of prophylaxis of depression in bipolar illness. Archives of General Psychiatry, 33, 117–20.
Dunner, D. L., Stallone, F. and Fieve, R. R. (1982). Prophylaxis with lithium carbonate: an update. Archives of General Psychiatry, 39, 1344–5.
Fieve, R. R. (1997). Moodswing (2nd edn). New York: Bantam Books.
Fieve, R. R., Kumbaraci, T. and Dunner, D. L. (1976). Lithium prophylaxis of depression in Bipolar I, Bipolar II, and unipolar patients. American Journal of Psychiatry, 133, 925–9.
Frank, E., Kupfer, D. J., Thase, M. E. et al. (2005). Two-year outcomes for interpersonal and social rhythm therapy in individuals with Bipolar I Disorder. Archives of General Psychiatry, 62, 996–1004.
Frye, M. A., Grunze, H., Suppes, T. et al. (2007). A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. American Journal of Psychiatry, 164, 1242–9.
Ghaemi, S. N., Hsu, D. J., Soldani, F. and Goodwin, F. K. (2003). Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders, 5, 421–33.
Goldberg, J. F., Burdick, K. E. and Endick, C. J. (2004). Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. American Journal of Psychiatry, 161, 564–6.
Goodwin, F. K., Murphy, D. L., Dunner, D. L. and Bunney, W. E. Jr. (1972). Lithium response in unipolar versus bipolar depression. American Journal of Psychiatry, 129, 44–7.
Greil, W. and Kleindienst, N. (1999). Lithium versus carbamazepine in the maintenance treatment of Bipolar II Disorder and Bipolar Disorder Not Otherwise Specified. International Clinical Psychopharmacology, 14, 283–5.
Greil, W., Ludwig-Mayerhofer, W., Erazo, N. et al. (1997). Lithium versus carbamazepine in the maintenance treatment of bipolar disorders: a randomised study. Journal of Affective Disorders, 43, 151–61.
Greil, W., Kleindienst, N., Erazo, N. and Müller-Oerlinghausen, B. (1998). Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. Journal of Clinical Psychopharmacology, 18, 455–60.
Haykal, R. F. and Akiskal, H. S. (1990). Bupropion as a promising approach to rapid-cycling Bipolar II patients. Journal of Clinical Psychiatry, 51, 450–5.
Himmelhoch, J. M., Thase, M. E., Mallinger, A. G. and Houck, P. (1991). Tranylcypromine versus imipramine in anergic bipolar depression. American Journal of Psychiatry, 1487, 910–16.
Hirschfeld, R. M., Williams, J. B., Spitzer, R. L. et al. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. American Journal of Psychiatry, 157, 1873–5.
Hirschfeld, R. M., Weisler, R. H., Raines, S. R. and Macfadden, W. (2006). Quetiapine in the treatment of anxiety in patients with Bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 67, 355–62.
Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of Bipolar II Disorder. Archives of General Psychiatry, 60, 261–9.
Kane, J. M., Quitkin, F. M., Rifkin, A. et al. (1982). Lithium carbonate and imipramine in the prophylaxis of unipolar and Bipolar II illness: a prospective, placebo-controlled comparison. Archives of General Psychiatry, 39, 1065–9.
Keck, P. E. Jr., Calabrese, J. R., McQuade, R. D. et al. for the Aripiprazole Study Group (2006). A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with Bipolar I Disorder. Journal of Clinical Psychiatry, 67, 626–37.
Lam, D. H., Watkins, E. R., Hayward, P. et al. (2003). A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Archives of General Psychiatry, 60, 145–52.
Lam, D. H., Hayward, P., Watkins, E. R., Wright, K. and Sham, P. (2005). Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years. American Journal of Psychiatry, 162, 324–9.
McIntyre, R. S., Brecher, M., Paulsson, B., Huizar, K. and Mullen, J. (2005). Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double-blind randomised, parallel-group, placebo-controlled trial. European Neuropsychopharmacology, 15, 573–85.
Miklowitz, D. J., George, E. L., Richards, J. A., Simoneau, T. L. and Suddath, R. L. (2003). A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Archives of General Psychiatry, 60, 904–12.
Nemeroff, C. B., Evans, D. L., Gyulai, L. et al. (2001). Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. American Journal of Psychiatry, 158, 906–12.
Nierenberg, A. A., Fava, M., Trivedi, M. H. et al. for the STAR∗D Study Team (2006a). A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR∗D report. American Journal of Psychiatry, 163, 1519–30; Quiz, 1665.
Nierenberg, A. A., Ostacher, M. J., Calabrese, J. R. et al. and STEP-BD Investigators (2006b). Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. American Journal of Psychiatry, 163, 210–16.
Peet, M. (1994). Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. British Journal of Psychiatry, 164, 549–50.
Post, R. M., Altshuler, L. L., Leverich, G. S. et al. (2006). Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. British Journal of Psychiatry, 189, 124–31.
Prien, R. F. (1984). NIMH report. Five-center study clarifies use of lithium and imipramine for recurrent affective disorders. Hospital and Community Psychiatry, 35, 1097–8.
Prien, R. F., Caffey, E. M. Jr. and Klett, C. J. (1973). Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Archives of General Psychiatry, 28, 337–41.
Quitkin, F., Rifkin, A., Kane, J., Ramos-Lorenzi, J. R. and Klein, D. F. (1978). Prophylactic effect of lithium and imipramine in unipolar and Bipolar II patients: a preliminary report. American Journal of Psychiatry, 135, 570–2.
Quitkin, F. M., Kane, J. M., Rifkin, A. et al. (1981). Lithium and imipramine in the prophylaxis of unipolar and Bipolar II depression: a prospective, placebo-controlled comparison. Psychopharmacology Bulletin, 17, 142–4.
Rea, M. M., Tompson, M. C., Miklowitz, D. J. et al. (2003). Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial. Journal of Consulting and Clinical Psychology, 71, 482–92.
Sachs, G., Altshuler, L., Ketter, T. et al. (2001). Divalproex versus placebo for the treatment of bipolar depression. 40th Annual Meeting of the American College of Neuropsychopharmacology, Waikaloa, Hawaii, December 9–13.
Scott, J., Paykel, E., Morriss, R. et al. (2006). Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. British Journal of Psychiatry, 188, 313–20.
Shelton, R. C., Williamson, D. J., Corya, S. A. et al. (2005). Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. Journal of Clinical Psychiatry, 66, 1289–97.
Thase, M. E., Macfadden, W., Weisler, R. H. for the BOLDER II Study Group (2006). Efficacy of quetiapine monotherapy in Bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of Clinical Psychopharmacology, 26, 600–9.
Tohen, M., Vieta, E., Calabrese, J. et al. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of Bipolar I depression. Archives of General Psychiatry, 60, 1079–88.
Tohen, M., Greil, W., Calabrese, J. R. et al. (2005). Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry, 162, 1281–90.
Tohen, M., Calabrese, J. R., Sachs, G. S. et al. (2006). Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with Bipolar I Disorder responding to acute treatment with olanzapine. American Journal of Psychiatry, 163, 247–56.
Tondo, L., Baldessarini, R. J., Floris, G. and Rudas, N. (1997). Effectiveness of restarting lithium treatment after its discontinuation in Bipolar I and Bipolar II disorders. American Journal of Psychiatry, 154, 548–50.
Tondo, L., Baldessarini, R. J., Hennen, J. and Floris, G. (1998). Lithium maintenance treatment of depression and mania in Bipolar I and Bipolar II disorders. American Journal of Psychiatry, 155, 638–45.
Vieta, E., Martinez-Aran, A., Goikolea, J. M. et al. (2002). A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Journal of Clinical Psychiatry, 63, 508–12.
Wehr, T. A. and Goodwin, F. K. (1979). Rapid cycling in manic-depressives induced by tricyclic antidepressants. Archives of General Psychiatry, 36, 555–9.
Winsberg, M. E., DeGolia, S. G., Strong, C. M. and Ketter, T. A. (2001). Divalproex therapy in medication-naive and mood-stabilizer-naive Bipolar II depression. Journal of Affective Disorders, 67, 207–12.
Zarate, C., Payne, J., Singh, J. et al. (2004). Pramipexole for Bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry, 56, 54–60.

Reference Title: REFERENCES

Reference Type: reference-list

Altshuler, L. L., Suppes, T., Black, D. O. et al. (2006). Lower switch rate in depressed patients with Bipolar II than Bipolar I disorder treated adjunctively with second-generation antidepressants. American Journal of Psychiatry, 163, 313–15.
Amsterdam, J. D., Garcia-Espana, F., Fawcett, J. et al. (1998). Efficacy and safety of fluoxetine in treating Bipolar II major depressive episode. Journal of Clinical Psychopharmacology, 18, 435–40.
Amsterdam, J. D. and Garcia-Espana, F. (2000). Venlafaxine monotherapy in women with Bipolar II and unipolar major depression. Journal of Affective Disorders, 59, 225–9.
Balazs, J., Benazzi, F., Rihmer, Z. et al. (2006). The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. Journal of Affective Disorders, 91, 133–8.
Bauer, M. S., Wisniewski, S. R., Marangell, L. B. et al. for the STEP-BD Investigators (2006). Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Journal of Clinical Psychiatry, 67, 48–55.
Benazzi, F. (1997). Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. Journal of Affective Disorders, 46, 73–7.
Benazzi, F. (2005a). Family history validation of a definition of mixed depression. Comprehensive Psychiatry, 46, 159–66.
Benazzi, F. (2005b). Suicidal ideation and depressive mixed states. Psychotherapy and Psychosomatics, 74, 61–2.
Benazzi, F. (2006). Mood patterns and classification in bipolar disorder. Current Opinion in Psychiatry, 19, 1–8.
Bottlender, R., Sato, T., Kleindienst, N., Strausz, A. and Moller, H.-J. (2004). Mixed depressive features predict maniform switch during treatment of depression in Bipolar I Disorder. Journal of Affective Disorders, 78, 149–52.
Calabrese, J. R., Bowden, C. L., Sachs, G. S. et al. (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with Bipolar I depression. Lamictal 602 Study Group. Journal of Clinical Psychiatry, 60, 79–88.
Calabrese, J. R., Suppes, T., Bowden, C. L. et al. (2000). A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. Journal of Clinical Psychiatry, 61, 841–50.
Calabrese, J. R., Keck, P. E. Jr., Macfadden, W. et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of Bipolar I or II depression. American Journal of Psychiatry, 162, 1351–60.
Frye, M. A., McElroy, S. L., Hellemann, G. et al. (2006). Clinical correlates associated with antidepressant-related mania. Toronto: Programme and abstracts of the American Psychiatric Association Annual Meeting (abstract NR215).
Goldberg, J. F., Truman, C. J., Fordis, J. et al. (2004). Antidepressant use during mixed states: naturalistic outcome data from the STEP-1000. Neuropsychopharmacology, 29, S144 (abstract).
Hirschfeld, R. M., Weisler, R. H., Raines, S. R. and Macfadden, W. for the BOLDER Study Group. (2006). Quetiapine in the treatment of anxiety in patients with Bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 67, 355–62.
Leverich, G. S., Altshuler, L. L., Frye, M. A. et al. (2006). Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. American Journal of Psychiatry, 163, 232–9.
McElroy, S. L., Kotwal, R., Kaneria, R. and Keck, P. E. Jr. (2006). Antidepressants and suicidal behavior in bipolar disorder. Bipolar Disorders, 8, 596–617.
Parker, G., Tully, L., Olley, A. and Hadzi-Pavlovic, D. (2006). SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of Affective Disorders, 92, 205–14.
Prien, R. F., Kupfer, D. J., Mansky, P. A. et al. (1984). Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Archives of General Psychiatry, 41, 1096–104.
Tondo, L., Baldessarini, R. J., Hennen, J. and Floris, G. (1998). Lithium maintenance treatment of depression and mania in Bipolar I and Bipolar II disorders. American Journal of Psychiatry, 155, 638–45.

Reference Title: REFERENCES

Reference Type: reference-list

Benazzi, F. (2003). Bipolar II depressive mixed state: finding a useful definition. Comprehensive Psychiatry, 44, 21–7.
Ghaemi, S. N., Ko, J. Y. and Goodwin, F. K. (2001). The bipolar spectrum and the antidepressant view of the world. Journal of Psychiatric Practice, 7, 287–97.
Leverich, G. S., Altshuler, L. L., Frye, M. A. et al. (2006). Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. American Journal of Psychiatry, 163, 232–9.
Peet, M. (1994). Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. British Journal of Psychiatry, 164, 549–50.
Sharma, V., Khan, M. and Smith, A. (2005). A closer look at treatment-resistant depression: is it due to a bipolar diathesis? Journal of Affective Disorders, 84, 251–7.
Wehr, T. A. and Goodwin, F. K. (1987). Can antidepressants cause mania and worsen the course of affective illness? American Journal of Psychiatry, 144, 1403–11.

Reference Title: REFERENCES

Reference Type: reference-list

Akiskal, H. S. (2002). Towards a new classification of bipolar disorders. In Bipolar Disorders. Clinical and Therapeutic Progress, ed. E. Vieta, pp. 185–215. Madrid: Panamericana.
Altshuler, L. L., Suppes, T., Black, D. O. et al. (2006). Lower switch rate in depressed patients with Bipolar II than Bipolar I Disorder treated adjunctively with second-generation antidepressants. American Journal of Psychiatry, 163, 313–15.
Colom, F. and Vieta, E. (2006). Psychoeducation Manual for Bipolar Disorder. New York: Cambridge University Press.
Coryell, W., Keller, M., Endicott, J. et al. (1989). Bipolar II illness: course and outcome over a five-year period. Psychological Medicine, 19, 129–41.
El-Mallakh, R., Weisler, R. H., Townsend, M. H. and Ginsberg, L. D. (2006). Bipolar II Disorder: current and future treatment options. Annals of Clinical Psychiatry, 18, 259–66.
Ghaemi, S. N., Hsu, D. J., Soldani, F. and Goodwin, F. K. (2003). Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders, 5, 421–33.
Parker, G., Tully, L., Olley, A. and Hadzi-Pavlovic, D. (2006). SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of Affective Disorders, 92, 205–14.
Suppes, T., Hirschfeld, R. M., Vieta, E. et al. (2007). Quetiapine for the treatment of Bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World Journal of Biological Psychiatry (in press).
Tohen, M., Vieta, E., Calabrese, J. et al. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of Bipolar I depression. Archives of General Psychiatry, 60, 1079–88.
Torrent, T., Martinez-Aran, A., Daban, C. et al. (2006). Cognitive impairment in Bipolar II Disorder. British Journal of Psychiatry, 189, 254–9.
Vieta, E. (2003). Case for caution, case for action. Bipolar Disorders, 5, 434–5.
Vieta, E. and Suppes, T. (2007). International Society for Bipolar Disorders Diagnostic Task Force on Bipolar II Disorder. Bipolar Disorders (in press).
Vieta, E., Colom, F., Martínez-Arán, A., Benabarre, A. and Gastó, C. (1999). Personality disorders in Bipolar II patients. Journal of Nervous and Mental Disease, 187, 245–8.
Vieta, E., Colom, F., Martínez-Arán, A. et al. (2000). Bipolar II Disorder and comorbidity. Comprehensive Psychiatry, 41, 339–43.
Vieta, E., Gastó, C., Colom, F. et al. (2001). The role of risperidone in Bipolar II: an open six-month study. Journal of Affective Disorders, 67, 213–19.
Vieta, E., Gastó, C., Otero, A., Nieto, E. and Vallejo, J. (1997). Differential features between Bipolar I and Bipolar II disorder. Comprehensive Psychiatry, 38, 98–101.
Zarate, C. A. Jr., Payne, J. L., Singh, J. et al. (2004). Pramipexole for Bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry, 56, 54–60.

Reference Title: REFERENCES

Reference Type: reference-list

Akiskal, H. S., Bourgeois, M. L., Angst, J. et al. (2000). Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. Journal of Affective Disorders, 59 (Suppl. 1), S5–30.
Akiskal, H. S. and Mallya, G. (1987). Criteria for the ‘soft’ bipolar spectrum: treatment implications. Psychopharmacology Bulletin, 23, 68–73.
Altshuler, L. L., Suppes, T., Black, D. O. et al. (2006). Lower switch rate in depressed patients with Bipolar II than Bipolar I Disorder treated adjunctively with second-generation antidepressants. American Journal of Psychiatry, 163, 313–15.
Fieve, R. R. and Dunner, D. L. (1975). Unipolar and bipolar affective states. In The Nature and Treatment of Depression, ed. F. F. Flach and S. S. Draghi, pp. 145–60. New York: John Wiley and Sons.
Hadjipavlou, G., Mok, H. and Yatham, L. N. (2004). Pharmacotherapy of Bipolar II Disorder: a critical review of current evidence. Bipolar Disorders, 6, 14–25.
Parker, G., Tully, L. and Hadzi-Pavlovic, D. (2006). SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of Affective Disorders, 92, 205–14.
RANZCP Clinical Practice Treatment Guideline on Bipolar Disorder (2004). Australian and New Zealand Journal of Psychiatry, 38, 280–305.
Rich, B. A., Schmajuk, M., Perez-Edgar, K. E. et al. (2007). Different psychophysiological and behavioral responses elicited by frustration in pediatric bipolar disorder and severe mood dysregulation. American Journal of Psychiatry, 164, 309–17.
Thase, M. E., Macfadden, W., Weisler, R. H. et al. (2006). Efficacy of quetiapine monotherapy in Bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER study). Journal of Clinical Psychopharmacology, 26, 600–9.
Zarate, C. A. Jr., Payne, J. L., Singh, J. et al. (2004). Pramipexole for Bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry, 56, 54–60.

Reference Title: REFERENCES

Reference Type: reference-list

Byrne, S. E. and Rothschild, A. J. (1998). Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. Journal of Clinical Psychiatry, 59, 279–88.
Calabrese, J. R., Keck, P. E. Jr., Macfadden, W. et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of Bipolar I or II depression. American Journal of Psychiatry, 162, 1351–60.
Goldberg, J. F., Bowden, C. L., Calabrese, J. R. et al. (2007). Six-month prospective life charting of mood symptoms with lamotrigine monotherapy versus placebo in rapid-cycling bipolar disorder. Biological Psychiatry (in press).
Ketter, T. A. and Calabrese, J. R. (2002). Stabilisation of mood from below versus above baseline in bipolar disorder: a new nomenclature. Journal of Clinical Psychiatry, 63, 146–51.

Reference Title: REFERENCES

Reference Type: reference-list

Altshuler, L., Kiriakos, L., Calcagno, J. et al. (2001). The impact of antidepressant discontinuation versus antidepressant continuation on one-year risk for relapse of bipolar depression: a retrospective chart review. Journal of Clinical Psychiatry, 62, 612–16.
Altshuler, L., Suppes, T., Black, D. et al. (2003). Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at one-year follow-up. American Journal of Psychiatry, 160, 1252–62.
Altshuler, L. L., Suppes, T., Black, D. O. et al. (2006). Lower switch rate in depressed patients with Bipolar II than Bipolar I disorder treated adjunctively with second-generation antidepressants. American Journal of Psychiatry, 163, 313–15.
Calabrese, J. R., Bowden, C. L., Sachs, G. S. et al. (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with Bipolar I depression. Lamictal 602 Study Group. Journal of Clinical Psychiatry, 60, 79–88.
Calabrese, J. R., Keck, P. E. Jr., Macfadden, W. et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of Bipolar I or II depression. American Journal of Psychiatry, 162, 1351–60.
Cunha, A. B., Frey, B. N., Andreazza, A. C. et al. (2006). Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neuroscience Letter, 398, 215–19.
Davis, L. L., Bartolucci, A. and Petty, F. (2005). Divalproex in the treatment of bipolar depression: a placebo-controlled study. Journal of Affective Disorders, 85, 259–66.
Frye, M. A., Ketter, T. A., Kimbrell, T. A. et al. (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology, 20, 607–14.
Jiang, W., Krishnan, R. R. and O'Connor, C. M. (2002). Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs, 16, 111–27.
Joffe, R. T., MacQueen, G. M., Marriott, M. and Young, L. T. (2005). One-year outcome with antidepressant treatment of bipolar depression. Acta Psychiatrica Scandinavica, 112, 105–9.
Keck, P. E. Jr., Perlis, R. H., Otto, M. W. et al. (2004). The Expert Consensus Guideline Series: Treatment of Bipolar Disorder 2004. Postgraduate Medicine, Dec., 1–120.
Kessing, L. V. and Nilsson, F. M. (2003). Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. Journal of Affective Disorders, 73, 261–9.
Kessing, L. V. and Andersen, P. K. (2004). Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? Journal of Neurology, Neurosurgery and Psychiatry, 75, 1662–6.
Koukopoulos, A., Sani, G., Koukopoulos, A. E. et al. (2003). Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. Journal of Affective Disorders, 73, 75–85.
Kupka, R. W., Luckenbaugh, D. A., Post, R. M. et al. (2005). Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. American Journal of Psychiatry, 162, 1273–80.
Leverich, G. S., Altshuler, L. L., Frye, M. A. et al. (2006). Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. American Journal of Psychiatry, 163, 232–9.
Malach, M. and Imperato, P. J. (2004). Depression and acute myocardial infarction. Preventative Cardiology, 7, 83–90.
Marangell, L. B., Martinez, J. M., Ketter, T. A. et al. (2004). Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. Bipolar Disorders, 6, 139–43.
McElroy, S. L., Suppes, T., Frye, M. A. et al. (2007). Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. Journal of Affective Disorders (in press).
Nickel, M. K., Muehlbacher, M., Nickel, C. et al. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry, 163, 833–8.
Nolen, W. A., Kupka, R. W., Hellemann, G. et al. (2007). Tranylcypromine versus lamotrigine as adjunctive treatment to a mood stabilizer in bipolar depression: an open randomized controlled study. Acta Psychiatrica Scandinavica (in press).
Obrocea, G. V., Dunn, R. M., Frye, M. A. et al. (2002). Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biological Psychiatry, 51, 253–60.
Post, R. M. (2007). Role of BDNF in bipolar and unipolar disorder: Clinical and theoretical implications. Journal of Psychiatric Research (in press).
Post, R. M., Speer, A. M., Obrocea, G. V. and Leverich, G. S. (2002). Acute and prophylactic effects of anticonvulsants in bipolar depression. Clinical Neuroscience Research, 2, 228–51.
Post, R. M., Altshuler, L. L., Leverich, G. S. et al. (2006). Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. British Journal of Psychiatry, 189, 124–31.
Rihmer, Z. and Pestality, P. (1999). Bipolar II Disorder and suicidal behavior. Psychiatric Clinics of North America, 22, 667–73.
Suppes, T., Mintz, J., McElroy, S. L. et al. (2005). Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment Network: a sex-specific phenomenon. Archives of General Psychiatry, 62, 1089–96.
Thase, M. E., Macfadden, W., Weisler, R. H. et al. (2006). Efficacy of quetiapine monotherapy in Bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of Clinical Psychopharmacology, 26, 600–9.
Winsberg, M. E., Degolia, S. G., Strong, C. M. and Ketter, T. A. (2001). Divalproex therapy in medication-naive and mood-stabilizer-naive Bipolar II depression. Journal of Affective Disorders, 67, 207–12.

Reference Title: REFERENCES

Reference Type: reference-list

Akiskal, H. S. and Benazzi, F. (2006). The DSM-IV and ICD-10 categories of recurrent [major] depressive and Bipolar II disorders: evidence that they lie on a dimensional spectrum. Journal of Affective Disorders, 92, 45–54.
Amsterdam, J. D. and Shults, J. (2005). Fluoxetine monotherapy of Bipolar Type II and Bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. International Clinical Psychopharmacology, 20, 257–64.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
Angst, J. (1998). The emerging epidemiology of hypomania and Bipolar II Disorder. Journal of Affective Disorders, 50, 143–51.
Angst, J. and Gamma, A. (2002). A new bipolar spectrum concept: a brief review. Bipolar Disorders, 4 (Suppl. 1), S11–14.
Angst, J., Gamma, A., Benazzi, F., Ajdacic, V., Eich, D. and Rossler, W. (2003). Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for Bipolar II, minor bipolar disorders and hypomania. Journal of Affective Disorders, 73, 133–46.
Benazzi, F. (2006). A continuity between Bipolar II depression and major depressive disorder? Progress in Neuropsychopharmacology and Biological Psychiatry, 30, 1043–50.
Calabrese, J. R., Keck, P. E. Jr, Macfadden, W. et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of Bipolar I or II depression. American Journal of Psychiatry, 162, 1351–60.
Dunner, D. L. (2005). Atypical antipsychotics: efficacy across bipolar disorder subpopulations. Journal of Clinical Psychiatry, 66 (Suppl. 3), S20–7.
Endicott, J., Rajagopalan, K., Minkwitz, M., Macfadden, W. and the BOLDER Study Group (2007). A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of Bipolar I and II depression: improvements in quality of life. International Clinical Psychopharmacology, 22, 29–37.
Ghaemi, S. N., Hsu, D. J., Soldani, F. and Goodwin, F. K. (2003). Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders, 5, 421–33.
Janenawasin, S., Wang, P. W., Lembke, A. et al. (2002). Olanzapine in diverse syndromal and sub-syndromal exacerbations of bipolar disorders. Bipolar Disorders, 4, 328–34.
Parker, G., Tully, L., Olley, A. and Hadzi-Pavlovic, D. (2006). SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of Affective Disorders, 92, 205–14.
Thase, M. E., Macfadden, W., Weisler, R. H. et al. for the BOLDER II Study Group (2006). Efficacy of quetiapine monotherapy in Bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of Clinical Psychopharmacology, 26, 600–9.
Vieta, E., Gasto, C., Colom, F. et al. (2001). Role of risperidone in Bipolar II: an open 6-month study. Journal of Affective Disorders, 67, 213–19.
Yatham, L. N. (2005). Diagnosis and management of patients with Bipolar II Disorder. Journal of Clinical Psychiatry, 66 (Suppl. 1), S13–17.
World Health Organization (1992). The ICD–10 Classification of Mental and Behavioural Disorders. Geneva: World Health Organization.

Reference Title: REFERENCES

Reference Type: reference-list

Lam, D. H., Watkins, E. R., Hayward, P. et al. (2003). Randomized controlled study of cognitive therapy for relapse prevention for Bipolar Affective Disorder: outcome of the first year. Archives of General Psychiatry, 60, 145–52.
Miller, J., Fletcher, K. and Kabat-Zinn, J. (1995). Three-year follow-up and clinical implications of a mindfulness meditation-based stress reduction intervention in the treatment of anxiety disorder. General Hospital Psychiatry, 17, 192–200.
Scott, J., Paykel, E., Morriss, R. et al. (2006). Cognitive-behavioural therapy for bipolar disorder. British Journal of Psychiatry, 188, 313–20.
Teasdale, J. D., Segal, Z. V., Williams, J. M. G. et al. (2000). The prevention of relapse/recurrence of major depression by mindfulness-based cognitive therapy. Journal of Consulting and Clinical Psychology, 68, 615–23.

Reference Title: REFERENCES

Reference Type: reference-list

Bauer, M. S. and Mitchner, L. (2004). What is a “mood stabilizer”? An evidence-based response. American Journal of Psychiatry, 161, 3–18.
Bowden, C. L., Grunze, H., Mullen, J. et al. (2005). A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Journal of Clinical Psychiatry, 66, 111–21.
Calabrese, J. R., Keck, P. E. Jr., Macfadden, W. et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of Bipolar I or II depression. American Journal of Psychiatry, 162, 1351–60.
Colom, F., Vieta, E., Sanchez-Moreno, J. et al. (2005). Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels. Bipolar Disorders, 7 (Suppl. 5), S32–6.
Guo, J. J., Keck, P. E. Jr., Corey-Lisle, P. K. et al. (2006). Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. Journal of Clinical Psychiatry, 67, 1055–61.
Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of Bipolar II Disorder. Archives of General Psychiatry, 60, 261–9.
Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2005). Psychosocial disability in the course of Bipolar I and II disorders: a prospective, comparative, longitudinal study. Archives of General Psychiatry, 62, 1322–30.
Keck, P. E. Jr., McElroy, S. L., Havens, J. R. et al. (2003). Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. Comprehensive Psychiatry, 44, 263–9.
Kupka, R. W., Luckenbaugh, D. A., Post, R. M. et al. (2005). Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. American Journal of Psychiatry, 162, 1273–80.
Nolen, W. A., Luckenbaugh, D. A., Altshuler, L. L. et al. (2004). Correlates of one-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. American Journal of Psychiatry, 161, 1447–54.
Perlis, R. H., Baker, R. W., Zarate, C. A. Jr. et al. (2006). Olanzapine versus risperidone in the treatment of manic or mixed states in Bipolar I Disorder: a randomized, double-blind trial. Journal of Clinical Psychiatry, 67, 1747–53.
Post, R. M., Denicoff, K. D., Leverich, G. S. et al. (2003). Morbidity in 258 bipolar outpatients followed for one year with daily prospective ratings on the NIMH life chart method. Journal of Clinical Psychiatry, 64, 680–90.
Schneck, C. D., Miklowitz, D. J., Calabrese, J. R. et al. (2004). Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program. American Journal of Psychiatry, 161, 1902–8.
Tohen, M., Greil, W., Calabrese, J. R. et al. (2005). Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American Journal of Psychiatry, 162, 1281–90.
Tohen, M., Ketter, T. A., Zarate, C. A. et al. (2003). Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. American Journal of Psychiatry, 160, 1263–71.

Reference Title: REFERENCES

Reference Type: reference-list

Altshuler, L. L., Post, R. M., Leverich, G. S. et al. (1995). Antidepressant-induced mania and cycle acceleration: a controversy revisited. American Journal of Psychiatry, 152, 1130–8.
Altshuler, L., Suppes, T., Black, D. et al. (2003). Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at one-year follow-up. American Journal of Psychiatry, 160, 1252–62.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: APA.
Amsterdam, J. D. and Shults, J. (2005). Fluoxetine monotherapy of Bipolar Type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. International Clinical Psychopharmacology, 20, 257–64.
Amsterdam, J. D., Garcia-Espana, F., Fawcett, J. et al. (1998). Efficacy and safety of fluoxetine in treating Bipolar II major depressive episode. Journal of Clinical Psychopharmacology, 18, 435–40.
Baldessarini, R. J., Leahy, L., Arcona, S. et al. (2007). Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatric Services, 58, 85–91.
Bauer, M., Adli, M., Baethge, C. et al. (2003). Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Canadian Journal of Psychiatry, 48, 440–8.
Blettner, M., Sauerbrei, W., Schlehofer, B., Scheuchenpflug, T. and Friedenreich, C. (1999). Traditional reviews, meta-analyses and pooled analyses in epidemiology. International Journal of Epidemiology, 28, 1–9.
Clayton, A. H., McGarvey, E. L., Clavet, G. J. and Piazza, L. (1997). Comparison of sexual functioning in clinical and non-clinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacology Bulletin, 33, 747–53.
Fox-Wasylyshyn, S. M. and El-Masri, M. M. (2005). Handling missing data in self-report measures. Research in Nursing and Health, 28, 488–95.
Ghaemi, S. N. (ed.) (2002). Polypharmacy in Psychiatry. New York: Marcel Dekker.
Ghaemi, S. N. (2003). Mood Disorders: A Practical Guide. Philadelphia: Lippincott, Williams, and Wilkins.
Ghaemi, S. N. (2006). Hippocrates and prozac: the controversy about antidepressants in bipolar disorder. Primary Psychiatry, 13, 52–8.
Ghaemi, S. N. and Goodwin, F. K. (2003). Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. Journal of Affective Disorders, 65, 167–71.
Ghaemi, S. N., Stoll, A. L. and Pope, H. G. (1995). Lack of insight in bipolar disorder: the acute manic episode. Journal of Nervous and Mental Disease, 183, 464–7.
Ghaemi, S. N., Katzow, J. J., Desai, S. P. and Goodwin, F. K. (1998). Gabapentin treatment of mood disorders: a preliminary study. Journal of Clinical Psychiatry, 59, 426–9.
Ghaemi, S. N., Boiman, E. E. and Goodwin, F. K. (2000). Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. Journal of Clinical Psychiatry, 61, 804–8.
Ghaemi, S. N., Manwani, S. G., Katzow, J. J., Ko, J. Y. and Goodwin, F. K. (2001). Topiramate treatment of bipolar spectrum disorders: a retrospective chart review. Annals of Clinical Psychiatry, 13, 185–9.
Ghaemi, S. N., Hsu, D. J., Soldani, F. and Goodwin, F. K. (2003). Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders, 5, 421–33.
Goodwin, F. and Jamison, K. (1990). Manic Depressive Illness. New York: Oxford University Press.
Goodwin, F. and Jamison, K. (2007). Manic Depressive Illness (2nd edn). New York: Oxford University Press.
Goodwin, G. M. and Young, A. H. (2003). The British Association for Psychopharmacology guidelines for treatment of bipolar disorder: a summary. Journal of Psychopharmacology, 17 (Suppl. 4), S3–6.
Hirschfeld, R. M. A., Bowden, C. L., Gitlin, M. J. et al. (2002). American Psychiatric Association practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry, 159, 1–50.
Hirschfeld, R., Clayton, P. and Cohen, I. (1994). Practice guidelines for the treatment of patients with bipolar disorder. American Journal of Psychiatry, 151, 1–31.
Holmes, O. W. (1891). Medical Essays 1842–1882. Boston: Houghton Mifflin and Company.
Inoue, T., Nakagawa, S., Kitaichi, Y. et al. (2006). Long-term outcome of antidepressant-refractory depression: the relevance of unrecognized bipolarity. Journal of Affective Disorders, 95, 61–7.
ISIS-2 (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet, 2, 349–60.
Jacobsen, F. M. (1993). Low-dose valproate: a new treatment for cyclothymia, mild rapid-cycling disorders, and premenstrual syndrome. Journal of Clinical Psychiatry, 54, 229–34.
Jouanna, J. (2001). Hippocrates. Baltimore, MD: Johns Hopkins University Press.
Kane, J. M., Quitkin, F. M., Rifkin, A. et al. (1982). Lithium carbonate and imipramine in the prophylaxis of unipolar and Bipolar II illness: a prospective, placebo-controlled comparison. Archives of General Psychiatry, 39, 1065–9.
Keck, P. E. Jr. and McElroy, S. L. (2003). New approaches in managing bipolar depression. Journal of Clinical Psychiatry, 64 (Suppl. 1), S13–18.
McHugh, P. R. (1996). Hippocrates à la mode. National Library of Medicine, 2, 507–9.
Mack, A. (2003). Examination of the evidence for off-label use of gabapentin. Journal of Managed Care Pharmacy, 9, 559–68.
Maclure, M. and Mittleman, M. A. (2000). Should we use a case-crossover design? Annual Review of Public Health, 21, 193–221.
Moller, H. J. and Grunze, H. (2000). Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? European Archives of Psychiatry and Clinical Neurosciences, 250, 57–68.
Moller, H. J., Grunze, H. and Broich, K. (2006). Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. European Archives of Psychiatry and Clinical Neurosciences, 256, 1–16.
Oxman, A. D. and Guyatt, G. H. (1992). A consumer's guide to sub-group analyses. Annals of Internal Medicine, 116, 78–84.
Parker, G. (2002). Do the newer antidepressants have mood stabilizing properties? Australian and New Zealand Journal of Psychiatry, 36, 427–8.
Parker, G. B., Malhi, G. S., Crawford, J. G. and Thase, M. E. (2005). Identifying ‘paradigm failures’ contributing to treatment-resistant depression. Journal of Affective Disorders, 87, 185–91.
Parker, G., Tully, L., Olley, A. and Hadzi-Pavlovic, D. (2006). SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. Journal of Affective Disorders, 92, 205–14.
Peet, M. (1994). Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. British Journal of Psychiatry, 164, 549–50.
Peirce, C. (1958). Selected Writings. New York: Dover Publications.
Rothman, K. J. (2002). Epidemiology: An Introduction. Oxford: Oxford University Press.
Rush, A. J., Trivedi, M. H., Wisniewski, S. R. et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. American Journal of Psychiatry, 163, 1905–17.
Sharma, V., Khan, M. and Smith, A. (2005). A closer look at treatment-resistant depression: is it due to a bipolar diathesis? Journal of Affective Disorders, 84, 251–7.
Soldani, F., Ghaemi, S. N. and Baldessarini, R. (2005). Research methods in psychiatric treatment studies. Critique and proposals. Acta Psychiatrica Scandinavica, 112, 1–3.
Sosenko, J. M. and Gardner, L. B. (1987). Attribute frequency and misclassification bias. Journal of Chronic Diseases, 40, 203–7.
Winsberg, M. E., DeGolia, S. G., Strong, C. M. and Ketter, T. A. (2001). Divalproex therapy in medication-naïve and mood-stabilizer-naïve bipolar II depression. Journal of Affective Disorders, 67, 207–12.

Reference Title: REFERENCES

Reference Type: reference-list

Angst, J. and Cassano, G. (2005). The mood spectrum: improving the diagnosis of bipolar disorder. Bipolar Disorders, 7 (Suppl. 4), S4–12.
Calabrese, J. R., Bowden, C. L., Sachs, G. S. et al. (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with Bipolar I depression. Lamictal 602 Study Group. Journal of Clinical Psychiatry, 60, 79–88.
Calabrese, J. R., Keck, P. E. Jr., Macfadden, W. et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of Bipolar I or II depression. American Journal of Psychiatry, 162, 1351–60.
Frye, M. A., Ketter, T. A., Kimbrell, T. A. et al. (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology, 20, 607–14.
Goodwin, G. M., Bowden, C. L., Calabrese, J. R. et al. (2004). A pooled analysis of two placebo-controlled 18-month trials of lamotrigine and lithium maintenance in Bipolar I Disorder. Journal of Clinical Psychiatry, 65, 432–41.
Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of Bipolar II Disorder. Archives of General Psychiatry, 60, 261–9.
Judd, L. L., Akiskal, H. S., Schettler, P. J. et al. (2005). Psychosocial disability in the course of Bipolar I and II disorders: a prospective, comparative, longitudinal study. Archives of General Psychiatry, 62, 1322–30.
Kupfer, D. J., Pickar, D., Himmelhoch, J. M. and Detre, T. P. (1975). Are there two types of unipolar depression? Archives of General Psychiatry, 32, 866–71.
Nierenberg, A. A., Ostacher, M. J., Calabrese, J. R. et al. (2006). Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. American Journal of Psychiatry, 163, 210–16.
Post, R. M., Altshuler, L. L., Leverich, G. S. et al. (2006). Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. British Journal of Psychiatry, 189, 124–31.
Thase, M. E. (2006). Pharmacotherapy of bipolar depression: an update. Current Psychiatry Reports, 8, 478–88.
Thase, M. E., Macfadden, W., Weisler, R. H. et al. for the BOLDER II Study Group (2006). Efficacy of quetiapine monotherapy in Bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of Clinical Psychopharmacology, 26, 600–9.
Tohen, M., Vieta, E., Calabrese, J. et al. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of Bipolar I depression. Archives of General Psychiatry, 60, 1079–88.
Vieta, E., Martinez-Aran, A., Goikolea, J. M. et al. (2002). A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Journal of Clinical Psychiatry, 63, 508–12.